Annual Report - JDRF Canada

Juvenile Diabetes Research Foundation (JDRF) is theglobal leader in setting the agenda for type 1 diabetesresearch worldwide, and is the largest charitable funderand advocate for type 1 diabetes research. Our mission isto find a cure for diabetes and its complications throughthe support of research.Founded in 1974 by parents of children with type 1diabetes, JDRF is passionate about our commitment toraising funds to drive world-class research to develop newand better treatments to improve the lives of people whohave type 1 diabetes and keep them as healthy aspossible.JDRF efficiently and effectively directs resources toresearch aimed at finding a cure and developing newtreatments, drugs and therapies. JDRF is committed toaggressively following the most promising paths to cure,better treat, and prevent type 1 diabetes.Through local chapters, international affiliates,volunteers, staff and corporate partnerships in over 100locations worldwide, JDRF offers a diverse supportnetwork, outreach programs, advocacy initiatives, andinnovative fundraising programs. For more information, orto make a donation, please visit www.jdrf.caIn 2005, JDRF International launched the Research toReality Campaign with the goal of raising $1 billion (U.S.)over five years to accelerate the cure for diabetes. JDRFCanada’s commitment toward that goal was $100 million.December 2009 marked the end of JDRF’s fiscal year andcontribution to the campaign. As a result of yourgenerosity, JDRF achieved an astounding $99,643,000!Thank you for your contributions to the success of thisambitious campaign.Table of CONTENTSLetter from Leadership . . . . . . . . . . . . . .2International Research Review 2009 . . . . . . . 3Donor Profiles: Our Partners. . . . . . . . . . . 9Our Successes . . . . . . . . . . . . . . . . . 23Outreach . . . . . . . . . . . . . . . . . . . . 27Government Relations . . . . . . . . . . . . . . 29Awareness . . . . . . . . . . . . . . . . . . . 31Continued Support. . . . . . . . . . . . . . . . 33Canadian Research Funded in 2009 . . . . . . . 37Financial Review 2009. . . . . . . . . . . . . . 40Directors & Chapters . . . . . . Inside Back CoverThe children, adults and families featured in this report are all fromthe JDRF Canada family.Front Cover:Front row: Mika, 4, diagnosed at 12 months of age; Evan, 6,diagnosed at 16 months of age.Middle Row: AudreyAnn, 12, diagnosed at 8 years of age;Montana, 13, diagnosed at 11 years of age; Keira, 6, diagnosedat 5 years of age; Leanne (Mother of Keira), 37, diagnosed at 21years of age; Myriam, 12, diagnosed at 2 years of age;Arnaud, 11, diagnosed at 2 years of age.Last Row: Luc, 51, diagnosed at 21 years of age; Raphaël, 19,diagnosed at 11 years of age; Kevin, 15, diagnosed at 8 yearsof age.

Montana, 13, diagnosedat 11 years of age[ 1 ]

Letter from LeadershipDespite the economicconservatism forecasted in2009, supporters of JuvenileDiabetes Research Foundation (JDRF)continued to understand the importanceof maintaining the strong momentumthe Foundation has created in diabetesresearch. As a result, the 2009 fiscalyear proved to be very impressivefinancially as we marked JDRF’s 35thyear in Canada.As we reflect on the dramaticadvancements in diabetes care and theprogress that has been made intranslating scientific discoveries intobetter treatments and cures fordiabetes, JDRF is reminded of thepassionate efforts of our foundingfamilies as they recognize the need fora charitable organization focused ondiabetes research.Fiscal year 2009 has also markedthe end of JDRF’s contribution toJuvenile Diabetes ResearchFoundation International’s (JDRFI)$1 billion (U.S.) From Research toReality Campaign. The goal of this fiveyear campaign was to accelerate thecure for diabetes. JDRF Canada’scommitment toward that goal was $100million. As a result of our dedicated andpassionate supporters, JDRFcontributed an astounding $99,643,000towards the international campaigntotal of $1,143,100,000.Over the past five years, JDRF hasmade dramatic advances in movingresearch into human clinical trials;more than in its previous 35 years ofresearch combined. JDRF has fundedmore than 44 human clinical trials, upfrom eight in 2000, and continued tospeed the pace of research byengaging industry. JDRF has over 25industry partnerships in every area ofresearch from stopping the immuneresponse to regenerating and replacingbeta cells to developing an artificialpancreas.Throughout the year, JDRFcontinued to spearhead breakthroughscience in pursuit of devices,technologies, potential therapies tohelp people control their diabetes andkeeping them healthier andcomplications-free until we find a cure.JDRFI’s groundbreaking continuousglucose monitor research — the firststep in our journey to build an artificialpancreas — generated excitement inthe scientific community and wasnamed one of the top scientificbreakthroughs of the year by ABCnews.In 2009, the Foundation also sawsuccess in a partnership that will speedthe innovative research opportunities atJDRF. Through government relationsefforts, and a unique partnership,JDRF and the Federal Government willlaunch a $33.9 million Clinical TrialNetwork. In November, JDRF Canadaannounced its first partnership with theGovernment of Canada through theFederal Economic DevelopmentAgency for Southern Ontario. Throughthis new two-year partnership, theGovernment of Canada is committing$20 million and JDRF is making amatching contribution of $13.9 million.JDRF will collaborate with University ofWaterloo and other researchinstitutions to accelerate world-classresearch by implementing a clinical trialnetwork for diabetes research. Thecreation of this clinical trial researchplatform focused on speedingadvances into cures and therapies fordiabetes and its complications, positionSouthern Ontario as an internationalhub for translational research; andattract the best international scientistsand institutions to Ontario.Today, JDRF is a global leader indiabetes research, the go-toorganization for the diabetes researchcommunity, and the best source forhope, better treatments as well ascures and therapies for people livingwith diabetes and its complications.Through the efforts of dedicatedvolunteers, donors, corporate partners,people impacted by the disease, aswell as family, friends, and staff, theFoundation is well positioned forsuccess in 2010 as it continues to driveresearch through the productdevelopment pipeline, and eventuallyinto the lives of those living withdiabetes. •Aubrey BaillieChair, Board of DirectorsAndrew McKeePresident and CEO[ 2 ]

International Research Review 2009JDRFI’s diabetes research portfoliois among the most innovative inthe world. It is the only portfoliofocused on multiple paths to a cure, onbetter treatments to keep people withdiabetes healthier, and on research forall stages of diabetes. This meansJDRFI research focuses on people whohave been living with diabetes foryears, sometimes decades; peoplewho are newly diagnosed, both childrenand adults; people with complications;and people who are at risk of gettingdiabetes.Core CommitmentsOur research is driven by four corecommitments: patients, priorities,partnerships, and pipeline.We are committed to keepingpatients at the forefront of everydecision we make—a true patientcentricfocus. We understand type 1diabetes can be different for each andevery person. Products and treatmentsbenefiting the newly diagnosed may beof less interest or no help to peoplewho have been living with diabetes for20 or 30 years. Drugs for complicationscan be life-changing for those sufferingfrom eye disease or kidney disease. Anartificial pancreas can benefit everyonewith type 1 diabetes—and many peoplewith type 2 diabetes as well—but it isnot a cure.At JDRFI, we fund research that hasshort-term objectives and looks todeliver treatments, as well as longertermgoals focused on definitive cures.We fund research that can impact eachand every stage of the disease. Wefund research that will lead to drugs,to compounds, and to devices andsystems.We are building cures andtreatments based on what patients tellus they want and need.We make choices about whatresearch to fund based on a set ofstrategic priorities. These prioritiescreate a framework that ensures thescience we choose to fund is the best,the most attractive, or holds thegreatest opportunity for success.First, we judge the “patient benefit,”the quality of improvement researchwould deliver, and the percentage ofpeople with type 1 diabetes who wouldbenefit. Then we look at the “time tobenefit,” or how long it will take todeliver a drug or treatment. Next is the“scientific impact,” or the potential ofthe research to advance science.Finally, we consider the “funding gap,”so we are only funding science thatotherwise would not be able to moveforward.We are creating partnerships tospeed the pace of research—partnerships with academia,businesses, governments, and otherpatient organizations. We have greatideas, and we fund more diabetesresearch than any other charitableorganization in the world. But that isnot enough.We need to work with the best andbrightest minds in academiclaboratories to create a steady streamof innovative ideas for treatments andcures. We need to partner with smallbiotech and device companies, whohave breakthrough products but needinitial funding to prove the promise ofthose concepts. We need to work withother nonprofits, to drive funding andattention to diabetes research andspecific projects. We need to partnerwith governments, who have theresources needed to create large scaleclinical programs. We need to workwith large pharmaceutical and diabetescompanies, who know how to bringtreatments and cures to market.Finally, we are well along the path ofexpanding the pipeline of “developmenttargets”—drugs, compounds, andtherapies to treat and cure diabetes.JDRFI’s research progress of the past40 years has brought us to the pointwhere we now need to translate greatideas and scientific advances intotangible treatments and cures fordiabetes. Moving candidates throughclinical testing and regulatory approvalis a lengthy and incredibly expensiveundertaking—so the more products wemove into the pipeline, the greater thechance people with diabetes willbenefit from them in both the near termand longer term.There has been exceptionalprogress to date in this area: JDRFI isfunding 44 human clinical trials today,more than ever before. And four are inPhase III trials—the final phase beforeregulatory approval.Cure, Treat, PreventJDRFI’s strategy is to approachresearch from a patient-centricperspective. We listen to people whohave type 1 diabetes to understandtheir hopes and fears, what their dailyroutine is like, and what they would bewilling and able to do to stay healthy.We ask them what a “cure” means tothem; and we get as many answers aspeople we ask.All people with type 1 diabetes wantdefinitive cures—a pill or injection orprocedure that restores their pancreasto a fully functional state. Some alsodefine a cure as a simpler and saferalternative to insulin, perhaps a pill ormultiple pills they take each day for therest of their lives, enabling them tomanage their diabetes better and moreeasily. Many focus on any regimen thatlowers their risk of the life-alteringcomplications of diabetes—somethingthat ensures they will not go blind, orhave kidney problems. For many, adevice that manages their diabetes—like a pacemaker for those with heartdisease—is a viable solution. Asignificant percentage of people withdiabetes also want to make sure not topass diabetes along to their childrenand grandchildren.That’s why the focus of JDRFI’sresearch strategy is to cure, treat, andprevent type 1 diabetes.The notion of “cure, treat, prevent” isa shorthand way of making certaineveryone with type 1 diabetes and their[ 3 ]

International Research Review 2009families understands JDRFI’s researchis focused on benefitting people atevery stage of the disease. We fundscience aimed at delivering cures, atdeveloping better treatments to serveas “a bridge to the cure,” and atstopping the disease before it takeshold in people at risk. Our research hasa mix of programs that have short-termhorizons—to provide benefits to peoplein the next five years or so—as well aslonger-term opportunities. Science inall those areas has always been a partof JDRFI’s research portfolio, andprogress has been made in each.Opportunities abound to cure, treat,and prevent type 1 diabetes and itscomplications.Therapeutic AreasJDRFI’s focus on curing, treating, andpreventing type 1 diabetes does notrequire a new mission or overallstrategy. Instead, we have narrowedour focus to four therapeutic areas.They are:Beta Cell TherapiesImmune TherapiesGlucose ControlComplications TherapiesEach of these areas incorporates theconcepts of curing, treating, andpreventing type 1 diabetes. They buildon the five cure therapeutics by whichwe have categorized our research forthe past several years.Beta Cell TherapiesAkey to curing diabetes isrestoring or revitalizing cells thatproduce insulin, which are lost inthe immune attack that causes type 1diabetes. That would bring back aperson’s ability to make their owninsulin again.JDRFI research focuses on twoways to restore that cell function:replacing or transplanting cells intosomeone with diabetes, or causing thebody to regenerate cells that produceinsulin.Replacement therapies includedonated islets, embryonic stem cells,adult stem cells, beta cell precursors,animal cells, or reprogrammed cells.Cell transplants for diabetes have hadlimited success to date, mostlybecause so few cells are donated andcan be transplanted. For those peoplewho receive transplants, the procedurecan reverse the significant problem ofhypoglycemia unawareness, in whichpeople cannot sense when their bloodsugar is dangerously low. Transplantsalso help people with very “brittle”diabetes to manage their diseasebetter. However, transplant recipientsrequire a lifelong regimen of drugs tosuppress the transplanted islets frombeing rejected by the immune system,which can cause a string of side effectsand complications.JDRFI is prioritizing beta cellregeneration and is already a leader inregeneration research. We have beeninvestigating and investing inregeneration for several years now andhave made progress to the point wherewe can begin to translate science intodrug targets. By understanding howbeta cells expand in situations likepregnancy, obesity, and childhoodgrowth, we can drive research toregenerate beta cells to restore insulinproduction in large numbers of peoplewith diabetes, which is not possiblewith current replacement therapies.Last year, JDRFI funded more than$39 million (U.S.) of research in BetaCell Therapies, including regeneration,replacement, potential new sources ofinsulin-producing cells, andencapsulation.Progress in Beta Cell TherapiesIn a major development this year,JDRFI created an innovativepartnership with the Genomics Instituteof the Novartis Research Foundation(GNF) to create a drug discovery anddevelopment platform for diabetestherapies. The JDRF-GNF partnershipshould jump-start the creation of amulti-product pipeline for beta cellregeneration, delivering a succession ofregeneration drug candidates to theclinic over the next four years. Foundedin 1999, GNF is a drug-discovery armof the Novartis Foundation. JDRFI willbe working with this experienced andhighly regarded scientific partner toquicken the pace of translating researchdiscoveries into therapeutics—drugs,compounds, and treatments for peoplewith type 1 diabetes. The program isone of the largest and mostcomprehensive collaborations inJDRFI’s 40-year history.In another important development,JDRFI researchers showed shorttreatments with two drugs that canincrease insulin-producing beta cellnumbers and slow their immunedestruction, enough to restore normalblood sugar levels and reversediabetes. Working in mice, researchersat the University of Alberta inEdmonton, Canada, found a therapycombining the two drugs (gastrin andglucagon-like peptide 1) had positiveeffects on both the immune system andregeneration. Together, the drugs stopthe immune mechanism that destroysbeta cells in type 1 diabetes, andpromotes cell growth and survival.Combining the two drugs offers apromising strategy for reversing betacell loss in people with the disease.The next step is a human clinicaltrial—and one of JDRFI’s industrypartners, Transition Therapeutics, Inc.,is teaming with Eli Lilly and Companyto develop gastrin-based therapies andto further speed testing anddevelopment.Also during the year, JDRFI-fundedresearchers showed that cells in thepancreas that normally do not makeinsulin can be changed into cells thatdo—boosting the prospect ofregeneration as a treatment for type 1[ 4 ]

International Research Review 2009diabetes. In a study with mice,scientists in Germany at the Max-Planck Institute for BiophysicalChemistry and the University ofGöttingen discovered by driving theexpression of a gene in non-insulinproducingalpha cells, they could turnthem into insulin-producing beta cells.The researchers targeted the genebecause it is known to regulate growth,development, and other key cellularfunctions. The newly formed beta cellsresulted in better glucose control andhelped the mice survive. The scientistsalso discovered the alpha cells thatbecame new beta cells came from“progenitor” cells in the pancreas, andthe drop in the number of alpha cellstriggered additional progenitor cells toreplace them. The findings illustratetwo potential cell targets forregeneration—progenitor cells andalpha cells—as well as a critical geneand a pathway that can be used toscreen for drugs that target these cells.Immune TherapiesAlong with restoring insulinproduction through beta celltherapies, a cure for type 1diabetes will involve turning off theimmune response that causes thedisease—a step critical to the survivalof regenerated or transplanted betacells. Immune Therapies would stop,reverse, and ultimately prevent theimmune attack that causes type 1diabetes.Most current immune therapiestarget the overall immune system—theydampen all autoimmune reactions toget at the ones that cause diabetes.Such “non-antigen-specific”approaches are useful, but they have agreater risk of side effects, and they donot address the specific underlyingimmune issues that cause diabetes.Antigen-specific therapies directlyfocus on the immune system causes ofdiabetes, and only on them. Antigenspecifictherapies have the potential togenerate safe, effective treatments.Scientists working in this area areinvestigating ways to create a more“tolerant” immune system. The mainstrategy is to eliminate those immunesystem cells that destroy insulinproducingbeta cells (they are called“effector T cells”) and to increase othertypes of cells that control andsuccessfully regulate the immunesystem (called “regulatory T cells”). Indiabetes, people have more of the cellsthat kill off beta cells than they do ofcells that control the immune system;restoring a balance would conceivablystop the immune reaction underlyingthe disease.A second research track withinImmune Therapies is focused ondeveloping preventive ImmuneTherapies and combination ImmuneTherapies. Here, scientists areassessing a range of possibleinterventions and approaches. Somewill use anti-inflammatory drugs tocontrol inflammation in people at riskof developing diabetes. Others willdevelop biomarkers that can helpindicate the risk of getting diabetes,as well as a patient’s response totreatments.Last year, JDRFI funded $33 million(U.S.) of Immune Therapies research—about one-third of all research itsupported over the course of the year.There are more human clinical trials inImmune Therapies—16 projects arecurrently underway—than in any otherarea of JDRFI’s research portfolio.Progress in Immune TherapiesJDRFI-funded researchers workedthroughout the year on developing anoral vaccine to control the autoimmuneresponse that causes type 1 diabetes.This unique approach is beingpioneered by the University ofMassachusetts Medical School.Researchers there are using hollow“yeast shells” to carry proteins andother agents that alter the behaviour ofimmune cells in the stomach. Thevaccine is intended to interrupt theimmune attack that causes diabetesand silence key genes that contribute toinflammation and autoimmunity. Ifeffective, the vaccine will retrain theimmune system to tolerate the insulinproducingbeta cells that are mistakenlytargeted and destroyed in type 1diabetes. This novel strategy is basedon a promising new approach forsilencing inflammatory reactions in theimmune system.A team of JDRFI-funded researchersin Australia completely prevented type 1diabetes in mice with a therapytargeting immune B cells, rather thanT cells. Most therapies to reverse theimmune response that causes diabetestarget T cells—the immune cells thatdestroy insulin-producing beta cells.But previous research has pointed to akey role for B cells. In the Australianresearch, mice that received a B celltherapy were completely protected fromdiabetes throughout the study’s 50weeks. However, mice not given thetherapy showed rising blood sugarlevels and eventually developeddiabetes. The researchers found thatB cell therapy prevents diabetes byreducing the total number of B cells inthe body. With less interaction betweenB and T cells, the disease is nottriggered. It also increases the numberof regulatory T cells, allowing theimmune system to “reign in” destructiveactivity from T cells. The findingsadvance our understanding of howdiabetes develops and progresses—and points to a potential new treatment:depleting the B cells may be a powerfultool for preventing and treating type 1diabetes in people.This year, two of JDRFI’s industrypartners entered into global allianceswith pharmaceutical companies todevelop and commercialize immunetherapies for people who have beennewly diagnosed with type 1 diabetes.During the past year, thesecollaborations moved the therapies tothe final stage of clinical testing. In onepartnership, between JDRFI partner[ 5 ]

International Research Review 2009MacroGenics and Eli Lilly and Company,a Phase III trial is testing an anti-CD3antibody that has been effective inslowing the progress of diabetes if takensoon after diagnosis. The second JDRFIpartner, Tolerx, formed an alliance withGlaxoSmithKline to develop anotheranti-CD3 antibody in Phase III trials.These developments demonstrate thesuccess of JDRFI’s strategy to fill gapsin the drug-development pipeline byfunding proof-of-concept trials forpromising cures and treatments, and byhelping small companies move researchthrough early clinical testing until biggercompanies step in and fund the largetrials needed for FDA approval.Glucose ControlGlucose Control research—formerly called MetabolicControl—aims to developmultiple approaches to restore tightblood glucose control for people at allstages of type 1 diabetes—fromnew-onset to those with longestablisheddisease.Research in this area is often seenas a “bridge to a cure.” Bettermanagement of diabetes will improvepeople’s quality of life, reduce their riskof developing complications, and helpother therapies work more effectively.Our constituents, particularly adults,have consistently told us this is anincredibly important part of whatJDRFI’s research should be delivering.In addition, the good glucose controlthese therapies can bring will be a keystarting point for ensuring biologicalcures and therapeutics are effectiveand long-lasting.One of the key goals of the GlucoseControl program is to develop aclosed-loop artificial pancreas. Thisdevice would revolutionize diabetescare by enabling people to achievetight blood sugar control while avoidingboth highs and dangerous lows,significantly reducing the risk of thedisease’s devastating complications.By creating systems that usecontinuous glucose monitoring, insulinpumps, and sophisticated computerprograms to tie the two together, weare looking to regulate glucose controlin people with diabetes by replicatinghow a pancreas functions. Over thepast year, JDRFI’s groundbreakingwork with CGM devices and closedloopsystems through our ArtificialPancreas Project has become animportant global branding tool forJDRFI, underscoring our innovation,our ability to partner, and our focuson patients.In addition to the artificial pancreas,JDRFI is actively working to developnovel insulins that are faster-acting,glucose-responsive, and easier to useand manage than existing approaches.Because both lines of research havesuch high potential to improve the livesof people with diabetes in the nearterm, JDRFI has prioritized them—designating the Closed-Loop ArtificialPancreas and Novel Insulins asstrategic programs that will receiveprioritized focus and funding. Alongsidethese efforts, scientists will also directtheir focus on identifying other drugsthat might improve glucose control,minimize or prevent hypoglycemia, andrestore hypoglycemia awareness.During the past year, JDRFI fundednearly $6 million (U.S.) of GlucoseControl research.Progress in Glucose ControlA breakthrough clinical trial funded byJDRFI last year found people who useCGMs to help manage their diabetesexperienced significant improvementsin blood sugar control. Results from thestudy were first published in theprestigious New England Journal ofMedicine, and then in additionalscientific journals throughout the year.The researchers studied people fromeight to 72 years old at ten academic,community, and managed-carepractices around the U.S. The resultsshowed people, particularly adults, whoused CGM devices improved theirdiabetes care by almost everymeasure—which translates into adramatic lowering of the risk ofcomplications. Patients in all ageranges who used the devices at leastsix days per week saw similar benefits.Most importantly, people were able tobetter control their diabetes withoutincreasing the risk for low blood sugaremergencies, which can be dangerous,and even deadly. In large part becauseof the CGM trial’s positive results,several major national health insurershave expanded their policies to includeor broaden coverage of CGM. ABCNews recognized the groundbreakingtrial as one of the top ten medicalbreakthroughs of the year. The trialsshowed that continuous glucosemonitors are more than simply devicesof convenience for people withdiabetes—they are tools that cansubstantially improve blood sugarcontrol in people of all ages when usedregularly, without increasing the risk ofdangerous low blood sugar. Thegrowing evidence of the benefits ofCGM underscores the importance ofcontinued research into a closed-loopartificial pancreas.Also during the past year, JDRFIentered into a partnership with thecompany SmartCells, Inc., to advancethe development of an insulin that is“self-regulating.” Taken just once a day,this new insulin is only activated inresponse to the body’s glucose levels.Unlike currently available insulins, thisbreakthrough product is designed tomaintain continuous, tight control ofblood sugar levels while reducing therisk of hypoglycemia—like thepancreas does automatically in peoplewithout type 1 diabetes. JDRFI isproviding funding to support clinicaltrials to show the insulin is both safeand effective. But the potential isevident already: an insulin needing tobe injected only once per day andreacts to blood sugar only whenneeded could mark a significantimprovement in treating diabetes,[ 6 ]

International Research Review 2009requiring fewer injections and lessblood sugar monitoring while alsoreducing hypoglycemia.Complications TherapiesLastly, JDRFI continues to focus ondeveloping therapies to preventand treat the complications thatcan strike people with diabetes:diseases of the eyes, nerves, kidneys,and blood vessels. The aim is to stopcomplications from starting and fromgetting worse, and to repair anydamage.Research within ComplicationsTherapies complements JDRFI’sefforts to restore or improve beta cellfunction, which also lowers the risks forcomplications. Complicationsprevention is a core focus of this area,because of its potential fortransformative breakthroughs thatcould help people live longer, healthierlives.One of the keys to prevention isunlocking the secrets of the genes andgene modifiers that protect somepeople from diabetes-relatedcomplications, particularly kidneydisease, regardless of how long theyhave the disease and how well they arein control. Through the study of“genetic resistance,” researchers arelooking to identify new gene targetsand pathways that can be translatedinto therapies to block complicationsfrom ever developing. By identifying thegenetic basis for resistance to thecomplications of diabetes, we can driveresearch that protects people fromdeveloping long-term complications.A second research track withinComplications Therapies focuses ondelivering early treatments to slow orstop complications that have alreadydeveloped, as well as developingtreatments that can reverse them. Thisresearch will involve identifyingpathways and targets that have beenlinked to diabetes-related eye, kidney,and nerve disease; developingbiomarkers of risk and progression;and conducting clinical trials ofpromising drug candidates.JDRFI funding for ComplicationsTherapies research totaled $22 million(U.S.) in FY2009.Progress in Complications TherapiesDuring the year, JDRFI researchersdiscovered two drugs—losartan orenalapril—used to treat high bloodpressure and can stop diabetes-relatedeye disease from progressing. Inhuman clinical trials, scientists at theUniversity of Minnesota showed thealready available drugs were effectivefor people with diabetes-relatedretinopathy, a serious and commoncomplication of type 1 diabetes thatoften leads to blindness. The study wasa five-year multi-centre trial involvingpeople with type 1 diabetes who hadnormal blood pressure, no signs ofkidney disease, and very mild eyedisease. After being treated with eitherof the two drugs, the patients were atleast two times less likely to have theirdiabetes-related retinopathy progressthan study participants who did not getthem. The findings suggest a potentialnew therapy for retinopathy, and furtherstudies are underway to establish howlong the protection lasts and whetherthe benefits continue if the treatment isstopped. The treatment will also betested in people with more advancedeye disease, high blood pressure, andkidney disease, since many people withdiabetes often also have thesecharacteristics.In another study last year, JDRFIresearchers discovered a link betweenlipid levels and the development andprogression of complications. Amulticenter study in the U.K. led by theJDRF/ Wellcome Trust Diabetes andInflammation Laboratory in Cambridgeshowed a significant number ofchildren and teenagers with type 1diabetes also have abnormal lipidlevels. These include higher-thanrecommendedlevels of cholesterol andtriglycerides. And people in the studywho had microalbuminuria— a sign ofearly kidney disease—had the highestcholesterol levels, suggesting lipidlevels play a role in developing thisdevastating complication. Although it iswell-known that abnormal lipid levels,such as high LDL (or “bad”) cholesterol,are a strong risk factor forcardiovascular disease, the discoverythat may play a role in the developmentof diabetes complications is new—pointing to a potential need for lipidmonitoring and management in peoplewith type 1 diabetes as a way toprevent complications beyondcardiovascular disease.Finally, human clinical trials of agene therapy showed promise inreversing and repairing diabetesrelatednerve damage. In Phase IItrials, JDRFI industry partner SangamoBioSciences reported its gene therapydrug stimulated nerve regrowth in thelegs, offering hope to people sufferingfrom diabetes-related neuropathy. Thetrial evaluated Sangamo’s therapy totreat mild to moderate nerve damage inthe legs in people with diabetes. Acommon diabetes-related complication,“peripheral sensory neuropathy” isassociated with the loss of small nervefibers in the arms and legs, oftenleading to a loss of sensation andmotor function as nerve damageprogresses. The Sangamo studyshowed the drug has a direct positiveeffect on nerve regrowth, and it is safe.People with diabetes-relatedneuropathy who were given the therapyhad a significant increase in thenumber of these small nerve fibers inthe skin. The therapy promotes theproduction of a specific protein linkedto nerve growth and function. Anincrease in these proteins may protectand repair nerve damage in peoplewith diabetes— while currenttreatments only address the painassociated with neuropathy.[ 7 ]

International Research Review 2009JDRFI Launches OnlineClinical Trials ServiceDuring the year, JDRFIsuccessfully launchedClinical Trials Connection(www.trials.jdrf.org), an innovativeonline service to help people withtype 1 diabetes and their familieseasily find information about clinicaltrials of treatments and cures fortype 1 diabetes and its complications.With more diabetes trials than everbefore, Clinical Trials Connectionsimplifies the process of finding studiesin which people might want to takepart. The website enables people tosearch the National Institutes ofHealth’s database of diabetes trials,including JDRFI-funded studies. Theservice offers users many benefits,including lists of all studies matchingtheir preferences and characteristics;the direct contact information of theresearchers conducting each trial; andautomatic e-mail updates.Over its 40 year history, JDRFI hasfunded more than $1.4 billion (U.S.)toward a cure, accelerating science tothe point where we are now fundingmore than 44 human clinical trials. Formany people with type 1 diabetes,getting information about trials, andmaking a decision to enroll in one, isdifficult, time-consuming, and oftenconfusing. Scientists are also finding itharder and harder to enroll participantsin clinical trials—making thedevelopment of better treatments andcures more costly and time-consuming.Clinical Trials Connection is one ofJDRFI’s responses to this situation. Todate, more than 10,000 people haveregistered with the service. •GlossaryAntigen-Specific Therapy: Therapies directly focusing on the specificimmune system causes of diabetes, and only on them, instead of damping theoverall immune system (as non–antigen-specific therapy does).B Cells: Cells involved in the immune system response that produceantibodies, rather than cell-mediated immune responses (those are T cells).Beta Cells: Cells within the pancreas that produce insulin in response toglucose in the bloodstream. They are destroyed by the immune system intype 1 diabetes.Closed-Loop: A system fully automating insulin delivery through a pump,based on continuous glucose monitoring of blood sugar levels. A fullyautomated artificial pancreas.Drug Development Pipeline: The process in which basic researchideas become treatments and cures, advancing from proof-of-concept toanimal studies to human clinical trials to regulatory approval and commercialdistribution.IDDP: JDRFI’s Industry Discovery and Development Partnership program, anovel research program that provides small biotech companies with fundingto advance targets for cures and treatments through proof-of-concept andearly stage clinical trials, until they can attract funding and commercializationagreements from large pharmaceutical and diabetes companies.Phase III Trials: The last phase of human clinical trials of a drug, treatment,or device before regulatory approvals.Reprogramming: Manipulating cells to change their function, such asconverting non-insulin-producing alpha cells in the pancreas into insulinproducingbeta cells.Self-regulating Insulin: Insulin that only activates in response to glucose inthe bloodstream. Taken once a day, it remains inert until needed, helping usersavoid hypoglycemia and better manage blood glucose.Stages of Diabetes: Diabetes as it progresses—from at-risk to newlydiagnosed to established disease, often including complications.T Cells: A type of immune cell. In diabetes, “effector T cells” destroy insulinproducingbeta cells and “regulatory T cells” regulate the immune system.[ 8 ]

Donor Profiles: Our PartnersRaphaël, 19, diagnosedat 11 years of age[ 9 ]

Scott BoltonCalgary, ABOffering business acumen to worthy causesScott Bolton believes in puttingwhat he has learned in his careerto use for charitable causes. Thatis why, within months of his 17 montholdson Ben being diagnosed with type 1diabetes, Scott was already on the boardof JDRF’s Calgary Chapter.“I’m a director of a number ofcharities: it’s my way of giving back,”explains Scott. “Those first few monthsafter Ben’s diagnosis were quitestressful for us. I got involved with theboard. At the same time, Ben’s motherKathleen, got involved in setting up asupport network for parents of newlydiagnosed children. You just want to dosomething and what better way thanjoining JDRF: an organization that isfocused on a cure.”Scott is not the only Bolton engagedin understanding diabetes and beinginvolved in the solution. Scott’s sister,Cydney, grew up with type 1 diabetes,and their father, Hugh Bolton, spent timeas the national chair of the CanadianDiabetes Association: a role currentlyoccupied by Scott’s brother-in-law BeauZahrai. Scott admires and encourageshis family’s volunteer efforts, whichcomplement his own work with JDRF,which he feels is more targeted tochildren and type 1 diabetes.Scott has been involved with JDRF atthe local chapter board level for 12years now, for the most part offering hisskills as an accountant. Over the yearshe has supported fundraising, includingthe TELUS Walk to Cure Diabetes,Galas, golf tournaments and the Ridefor Diabetes Research. In the last fewyears, Scott has joined forces with otherconnected business professionals tofocus on major gift fundraising.“As co-chair of the local major giftscommittee, my focus is now on targetingsuccessful Calgary business people.Grassroots fundraising events are thebackbone of the organization, but we’reworking to supplement them with majorgifts, which are very cost-effective,”says Scott. “There are many folks inCalgary who are both able to give andaffected by diabetes. Here in Alberta,they see tangible evidence of theirinvestment.” Scott points to a rich andongoing history of Albertan innovatorscontributing to an eventual cure, citingthe first batch of insulin ever made andthe Edmonton Protocol as examples.Though Ben’s diagnosis was thetrigger for Scott’s involvement, hisloyalty to JDRF is strengthened by theorganization’s focus on a cure for type 1diabetes and their disciplined, scientificapproach to allocating funds.“JDRF is the leader in effectivestewardship of donations. You can beassured funds will get to where youexpect them to,” says Scott. “TheFoundation has always maintained itsprinciple objective and as long as youkeep that mandate front and centre,chances are you’re going to succeed.Their focus will ultimately allow us torealize our goal of beating thisdisease.” •

Thomas Alan BuddKelowna, BCA man of means who means well!Afew years ago, Thomas Budd’sson, Dillon, came home fromkindergarten, very sad histeacher was going to be away. Tom wentin to speak to her. Dillon’s teacher, Kelly,explained to him her own young son hadbeen diagnosed with type 1 diabetes andshe needed to dedicate some time totake care of him. As Tom learned moreabout diabetes and the impact it wasgoing to have on his son’s favouriteteacher, he was moved to get involved.“I was touched by Kelly’s story, andby the widespread nature of diabetes.Kelly was such a good teacher to myson, and I wanted to find a way tosupport her,” explains Tom. “She told meabout JDRF and how she was planningon getting involved. I started out bymaking a donation, and my involvementwith the Foundation grew from there.Tom is a retired investment banker,and according to his own description, hehas amassed more wealth than heneeds – in fact, more than he could everspend. That’s why he set up afoundation several years ago in supportof community programs and charities: touse the money he has made in hiscareer to help others who need it.“I spend a fair bit of time listening andlooking for causes in need and ways todonate. I support health, arts, sports,children’s charities and communityinfrastructure in Kelowna,” says Tom.“My style is to get involved in anorganization’s main fundraising eventand try to set the bar with largedonations: hopefully challenging othersto do the same.”Over the years, Tom has taken thelead sponsorship role at a number ofJDRF events, including the localStarlight Gala in Kelowna. Hiscontributions have included gifts, suchas cruise ship vacations for silentauctions and cash donations in therange of $10,000 to $30,000 each year.Tom’s spirit of competition works wellwith driving up the ‘bids for a cure’ atthe Foundation’s feature Fund-A-Cureauction held at each Gala.“JDRF has a high level of supportfrom their volunteers – more than othercharities I’ve encountered. Everyoneinvolved really takes ownership andresponsibility for finding a cure, andthey make me feel this is something wecan accomplish together,” says Tom.“You don’t have to have the disease toget involved. If youaren’t personallytouched by diabetes,think about howfortunate you are andhelp out. The familiesgive so much time andthose of us who cangive, should supportthem. Writing a chequeis the easy part.” •

Building Trades of Alberta Charitable FoundationEdmonton, ABHelping others makes this brotherhood strongerEverybody knows someoneaffected by diabetes – it’severywhere. And the verypervasiveness of diabetes is whatinspired the Building Trades of Alberta toget behind JDRF.“From the beginning of ourinvolvement with JDRF, their staff wasfriendly and treated the building tradeswith respect,” explains Irene Fraleigh,Building Trades of Alberta (BTA)Charitable Foundation Coordinator.“They are accommodating andwelcoming and provide the informationwe need. JDRF makes it easy for us tosupport them.”The Building Trades of Alberta, whichrepresents construction trade unionmembers across Alberta, first becameinvolved in supporting JDRF in 1991 withthe Dollars Against Diabetes golftournament and other fundraisers. Theirsupport of JDRF and other organizationswas built over the years and in 2001 theyformed the BTA Charitable Foundation,which has supported diabetes researchsince day one.“In everything we do, we think aboutwhat has the potential to positivelyimpact our members,” explains RonHarry, President of the CharitableFoundation. “Since diabetes is sopervasive, we feel that supporting theresearch has the greatest potential tomake that impact.”The BTA Charitable Foundation isextremely active in the community,having donated over $3 million to manylocal causes. However, diabetesresearch is the top priority. The BTAFoundation has been a major sponsor ofthe local Denim & Diamonds gala for anumber of years, providing $25,000 insupport in 2008 and 2009.Most remarkable about the BTAFoundation’s contribution is the sourceof the money: the workers themselves.Ninety per cent of the money raised bythe Foundation happens on unionizedconstruction sites across Alberta. Thiseffort requires cooperation from theowners of the construction sites, thecontractors and most importantly, thevolunteers, who interrupt their owncoffee and lunch breaks to sell tickets.These hard working heroes raised$669,000 through ticket sales in 2009.The BTA Charitable Foundation’sefforts have also had a ripple effect.When affiliate unions have golftournaments and other fundraisingactivities, they will often direct themoney raised to JDRF because it is acause supported by the BTA.“As workers, we are blessed to havegainful and respectful employment. Wefeel strongly that we are a family and abrotherhood,” says Harry. “We think it’simportant to recognize and share thegood things in life and that by doing so,we will all be stronger.” •

Mike FairSmiths Falls, ONAn important spoke in a big wheelAnormal life for children with type 1diabetes, free from needles andno finger pokes: this goal is whatkeeps Mike Fair committed to supportingJDRF.Twenty-eight years ago, Mike’sdaughter, Merridee was diagnosed withtype 1 diabetes at 10 years of age.Since Merridee’s diagnosis, Mike haswitnessed not only his daughter’sstruggle with the condition, but that ofother children around her.“When Merridee was first diagnosed,we went to groups in the area. Watchingthe kids learning to give themselvesneedles at such a young age reallystrikes your heart,” says Mike. “Morethan 20 years after my daughter’sdiagnosis, we still do not have a cure fora disease that affects so many children’slives.”Mike is an established businessmanwith a reputation in his community fordoing good work. Owner of a new cardealership in Smiths Falls, Ontario, Mikebelieves in using his name, connectionsand reputation to give back to thecommunity which has supported hisbusiness: which he does for a number ofworthwhile causes.Twenty years ago, Mike and his goodfriend, hockey legend Bobby Orr, cameup with the idea of running a golftournament to raise funds for JDRF.Both avid golfers, they felt with Mr. Orr’snotoriety throughout the hockey world,they would be able to bring in a goodfield of hockey players, and as a result,participants in a tournament.They were right. Mike explains that inthe history of the event, they did notneed to promote it. Simply remindingfolks the event was approaching wasenough to attract 150 to 160 golfersevery year after the first. In the event’s17 year history, they raised over$365,000.Several years ago Mr. Orr stoppeddoing personal golf appearances, and2007 marked the last year for the golftournament. However, looking into thepossibility of being involved in one moretournament in 2011 in memory ofMerridee, who sadly, after living withdiabetes for most of her life and whowas on dialysis for the last ten years,passed away on June 28, 2009.“After the last tournament, I willcontinue to be involved in other ways,”says Mike. “I’ve seen what diabetes hasdone to other children and I have lostmy daughter at such a young age. It’smy hope that this won’t have to happento other parents and I will do my part.”Mike points out that type 1 diabetesis a worldwide concern that knows noboundaries – which is what makessupporting an international organizationso important. “I’m just a little spoke, butspokes make up the wheel and we needto keep that wheel turning until we find acure.” •

Great-West LifeWinnipeg, MBBuilding Stronger Communities TogetherFrom east to west, Great-West Lifeproudly supported JuvenileDiabetes Research Foundation(JDRF) in 2009, demonstrating acommitment that resulted in acontribution of more than $30,000towards the Foundation’s paths to acure.Staff and financial security advisorsin Northern Ontario, British Columbia,and Manitoba took part in two of theFoundation’s national events, and raised$15,000 in donations.Through the national corporatecitizenship program, Great-West Life,London Life and Canada Life providedan additional $15,000 in matching fundsin support of the various teamsfundraising efforts.“Time and again, we see the peopleof Great-West Life, London Life andCanada Life take up the challenge tobuild stronger communities togetherwith charities they believe in,” said JanBelanger, Assistant Vice-President ofCommunity Affairs, Great-West Life,London Life and Canada Life.“We’ve supported JDRF for over 20years, thanks in part to those staff andfinancial security advisors who havegiven their time and energy to help theFoundation achieve its goals.”Dan Bedard, a network supporttechnical specialist with Great-West Lifewas the captain of a corporate team forthe Winnipeg chapter of the 2009 Ridefor Diabetes Research.While Dan has supported othercharitable organizations in the past,type 1 diabetes affects him on a verypersonal level. His mother has diabetes,and just last year, a good friend of hiswas also diagnosed.Michael Hector Ponti, a financialsecurity advisor with Freedom 55Financial, the financial security planningdivision of London Life, led a team of 12on Vancouver Island, and raised over$6,000 for the 2009 TELUS Walk toCure Diabetes. Ponti also has a familymember with type 1 diabetes – his23-year-old son, Anand, who wasdiagnosed when he was 14.Ponti explained how diabetes affectsfamilies in many ways people do noteven realize.“It’s all the things we take for granted;like grocery shopping,” he said. “Whenyou have diabetes, it’s not just shoppingfor groceries - it’s about counting thecarbs in your food.”For Bedard and Ponti, the mostimportant contribution JDRF can makeis by continuing to fund research.“We need to find a cure,” Ponti said.“Millions of Canadians, especiallychildren, are affected by this disease,and the only way to find a cure is bydoing research.” •From left to right: Jack Swan, Peter Vincenten,Sean Beggs, Ronald Peterson, Dan Bedard

Kaese FamilyNanaimo, BCCommitted to Creating Hope for a CureWow Factor: that’s what theKaese family has brought totheir community of Nanaimo,BC and to the local JDRF chapter, sincethe diagnosis of their youngest son,Jake, at age eight.Following Jake’s diagnosis with type 1diabetes, Jacqui and Trent Kaese begantheir journey of raising funds in support ofJDRF. Their involvement in Foundationevents has enabled them to lead thecharge in both the Promise Ball and theGala of Hope fundraisers. Both theirpassion, dedication and involvementdoesn’t stop here. Jacqui also serves asa committee member on both Galacommittees as the Creative Directorwhich allows the Kaese family to connectto a network of affected families.Seven years later, Jacqui’s voice stillfalters when she recalls her firstmeeting with the Graetz family – who isalso a mother living with two childrenwith type 1 diabetes: “Paddy gave me asilver ingot, inscribed with an angel andthe word ‘hope’. She pressed it into myhand and said, ‘There is somebody herefor you.’” The value of this supportincreased even further two years laterwhen older son, Josh Kaese, wasdiagnosed with type 1 diabetes at age12. The Kaeses made it their mission topay it forward.Initially involved in the TELUS Walkto Cure Diabetes, the success-orientedKaese family did not stop there. Oneyear after Jake’s diagnosis, theylaunched Shots for Kids which is in itsseventh year, a weekend of hockey andgolf, featuring NHL Alumni and othercelebrities. In the first year, this eventraised $12,000 and has grown to$40,000 each year for the last threeyears.Next up, Jacqui devised her Women’sWhyne Festival, an evening fundraiserfor JDRF, celebrating all mothers caringfor sick children. Initially raising $5,000,the event now brings in $10,000annually.“We’re very lucky to be well-known inthe community, with influential friendsand celebrity clients ready to standbehind our cause,” says Jacqui, anaward-winning entertainment manager,whose husband Trent played for theNHL Buffalo Sabres team. “This puts usin a strong position to make a differenceand support a wonderful foundation thatfights for families like us on a dailybasis.”Recognizing the message of ‘hope’pressed into her palm five years earlier,Jacqui was inspired to lead the Gala ofHope in 2008. The results of the eventexceeded all expectations by raising$113,000 in the first year and again inthe second year, despite the economicdownturn.The Kaese family is motivated byJDRF’s focus on children, and on thesearch for a cure, along with theFoundation’s international reputation forresults, research excellence, carefulallocation of funds, and transparency.Jacqui feels some of the most promisingwork is in the clinical trials, which makeprogress so tangible, and the ArtificialPancreas Project, which strengthens herhope for an insulin-free future for hersons.“Diabetes is bigger than anyindividual, community or even country,”Jacqui explains, pointing to theextremely short life expectancies ofchildren with type 1 diabetes indeveloping nations. “A cure would beincredible for Canadian children likemine: but imagine the magnitude of theimpact on a global scale. JDRF is doingthis work globally: time is of the essenceto get on board.” •

Dr. Bernard LeibelToronto, ON15th anniversary of diabetes champion’s passingFifteen years ago, one of Canada’sleading scientific researchers,Dr. Bernard Leibel, passed awayjust one day before his 81st birthday.Dr. Leibel was a tireless and passionatediabetes researcher whose impressivecareer spanned 60 years. Dr. Leibel’slegacy has lived on in the numerousadvancements in diabetes research thathave been made since his passing in1995.“As a young man, my husbandBernard had the opportunity to work asa student researcher for Dr. FrederickBanting, the world-renowned Canadianwho co-discovered insulin with Dr.Charles Best,” says Dr. Leibel’s wife,Queenie. “That most remarkableexperience ignited in Bernard a passionfor research that stayed with himthroughout his life.”Dr. Leibel may be best known for hiscontributions to the development of thefirst pressure-sensitive helmet – aprecursor to modern day astronautequipment – and the creation of the firstartificial respirator for polio patients,which became known as the iron lung.But for families and children affected,his dedication to investigating type 1diabetes is most treasured.One of the founding members ofJDRF’s Toronto Chapter, Dr. Leibel’slifelong passion lay in solving themedical challenges associated withdiabetes. Over the years, he contributedto advancements in areas such asinsulin quality and delivery methods.Just before his death, Dr. Leibelcompleted his final research project,successfully implanting insulinproducingcells in laboratory animalswithout the use of immunosuppressivedrugs: a major breakthrough.“After working with him as a student,my husband dedicated the rest of his lifeto research that would expand on Dr.Banting’s work,” explains Queenie. “Hewas unrivalled in his commitment toimproving the lives of everyone affectedby diabetes and he worked diligently,until the end of his days, toward findinga cure.”Dr. Leibel’s work has opened upmany research possibilities, paving theway for today’s dedicated doctors andscientists. In honour of his manycontributions to the field of diabetesresearch, in 1996, JDRF established theDr. Bernard Leibel Diabetes Cure Fund.Through this Fund, the Foundation hasraised hundreds of thousands of dollarsto further explore and build upon hisbreakthroughs: moving closer tounderstanding the cause, cure andprevention of diabetes.“Bernard’s dream was to find a curefor type 1 diabetes,” says Queenie,“Because of him, and the researcherswho have followed in his footsteps,today, that dream is within our grasp.” •

Little FamilyMississauga, ONMaking a difference is serious businessThrough their business, Lucy’sSeafood Kitchen in Mississauga,Ontario, Len and Lucy Little haveliterally supported thousands of charityevents. From local hockey teams tocancer or multiple sclerosis, they neversay no to a request, donating hundredsof gift certificates annually for use atlocal raffles and silent auctions. Butwhen their son Luke was diagnosed withtype 1 diabetes just after his fourthbirthday, their charitable involvementbecame much more personal.“We gravitated toward JDRF becauseof their focus on type 1 diabetes andchildren, and their commitment to acure,” explains Len. “They make it veryattractive and easy to become loyalsupporters by offering real change andthe ability to make a difference. I feelwith any small effort we make to supportJDRF, our help is leveragedexponentially.”This business-oriented outlook isreflected in Len and Lucy’scontributions. Len sees their role ashelping to raise awareness of theFoundation and looking for creativeways to reduce the overhead andoperating costs of the region. Forexample, among many contributions,Lucy’s Seafood Kitchen has providedfood service to the Ride for DiabetesResearch and a venue for a localcorporate fundraising breakfast. Len hasalso taken on leadership roles, includingthe local TELUS Walk to Cure DiabetesChair for the last two years and morerecently, Chair of the newly establishedPeel Region Chapter.“Every single time I see a young childaffected by type 1 diabetes, it’s equallygut wrenching. I know from Luke’sexperience what effect diabetes has ontheir lives and I want to help,” says Len.“Ultimately, we all want a cure. However,the progress in research and theinnovations that have helped withimproving long-term diabetesmanagement are encouraging.JDRF has a strong process toanalyze and assess the return oninvestment of different areas ofresearch, and they are open tolooking at all differentavenues.”Len also points to the role of JDRF incommunities: giving families a place towhich they can turn. Often, when theyfind each other they are able to offermuch-needed mentorship and support.Not long ago, the Little family – whichalso includes Luke’s twin brother Liamand their sisters Lisa and LeeAnne– were able to help another family withdiabetes-friendly baby-sitting andinsights on lifestyle issues such asmanaging diabetes while playinghockey.Len is appreciative of the tremendoussupport of the local community that haspulled together in support of thediabetes cause, including JDRF staff,families and fellow volunteers, localcorporations and the police and firedepartments: “Sometimes thechallenges that are brought to us in lifeallow us to be exposed to, andexperience a new family: it’s veryreassuring to be surrounded by peopleworking toward a common goal.” •

Millard FamilyWaterloo, ONWhen it comes to making things happen,this family rocks!According to Paul Millard, there arethree kinds of people: those whomake things happen, those whowatch things happen and those whohave no idea what is happening. Pauland his family definitely choose the firstpath: making things happen.“I believe everyone needs to give,without expecting something in return.Give what you can: time, commitment ormoney,” says Paul in describing hisoutlook on life, “As a family, we are justdetermined to do something.” And theydo.Paul’s family includes his son Kyle,18, his daughter Melissa, 13, and hiswife Karen, whom he describes as thecatalyst of the family. It was Karen’sidea, after Melissa’s diagnosis withtype 1 diabetes, that the family puttogether a fundraiser for JDRF: afundraiser that makes the most of Paul’stalents and connections as a musician.Thus, Jammin’ for JD was born in2005 and has sold out every year sincethen. Part rock concert, part dance, theevent draws an enthusiastic crowd ofpeople interested in a great cause and agreat event. Raising $3,800 in the firstyear, the Millard family eventually had tomove the event to accommodategrowing numbers and in 2009 raisedover $10,000.“We always do our part to supportgood causes. In fact, we were involvedwith the Walk to Cure Diabetes beforeMelissa was diagnosed in February2005. Once we faced the reality of whatit means to have diabetes in the family,we wanted to do something more,”explains Paul. “Everyone in the familyas well as volunteers, pitch in to thisevent. For example, Melissa managesour online presence, Kyle plays bass inthe band and our volunteers network theticket sales and help run the events. Weare passionate about it as a family: wewant to find a cure.”A family that ‘makes things happen’,the Millards were attracted to supportingJDRF: an organization that does thesame. While a cure is the ultimate goal,Paul is optimistic about the progresshe’s seen in areas such as clinical trials- including a recent $30 millionpartnership between JDRF and thefederal government - and thedevelopment of the artificial pancreas.Paul is pleased with the information thefamily receives from the Foundation,including regular updates on where themoney is going and constant contactabout events and opportunities.“JDRF offers a really good network,connecting families across the country.Our role as affected families is to getout there and join the fight,” says Paul.“We will have a cure: it’s just a matter oftime. The more people who get involved,the quicker we will get there.” •

Denis PellerinMontreal , QCHelping people live, helping them healWhen Denis Pellerin’s son wasdiagnosed with type 1 diabetesat the age of 18, it changed hislife and those of everyone in his family.For a young man, just setting out on hisadult life, it was a difficult situation toaccept.“At the time, I focused all of myenergy on ensuring his survival, helpinghim learn to live with diabetes,”explained Mr. Pellerin, Senior VicePresident and Chief Risk Officer,National Bank Financial Group (NBFG).It was only later, once his son’s situationhad stabilized, this family man got reallyinvolved with Juvenile DiabetesResearch Foundation (JDRF). After fourstressful years, his son graduallyaccepted his disease and learned to liveaccordingly. “That’s when I realized Ihad helped him live, but not heal.” Therewas still a lot of work to be done.Like all executives at NBFG,Mr. Pellerin was encouraged tocontribute to good causes and wassolicited by many people. One day inJuly 2004, he received a request thattouched him: would he act as aspokesman for the Ride for DiabetesResearch for the NBFG employees inMontreal? Despite the fact the eventwas to take place, in September, DenisPellerin did not hesitate. With his firstgeneral appeal, he recruited 40 people(eight teams of five) who relayed oneanother on stationary bikes, to raise$11,000.“This experience was so positive,”Mr. Pellerin said. “When I did the roundsto thank my colleagues, they thankedme for my commitment!” As a result, heagreed to co-chair the next campaignand made it his goal to expand thescope of the event.The Team Captains for the first yearmet to brainstorm and get motivated.When talking with them, Mr. Pellerinnoted everyone knew someone withdiabetes. “As soon as we talked aboutour children, we became very emotional.I realized this was our motivation andour strength.”The results were not long in coming.In 2005, 40 NBFG teams participated inthe Montreal Ride and this number grewto 135 by 2009! Mr. Pellerin also pointsout that every person who pedalsusually has five or six colleagues whocontribute. This provides an idea of justhow much ground the event has gainedwithin the NBFG, where Montrealemployees alone gave JDRF a chequefor more than $200,000 last year.When Denis Pellerin was asked toexplain this success, heexplained his three-stepsystem:1. Do what you askothers to do, act, setthe example.2. Count on yournetwork, the firmwhere you are solidlyestablished, thepeople who trust youor owe you a favour.3. When you need aspokesperson, findsomeone who takesthe cause to heart,who speaks withconviction and whowill touch the peoplearound them.This is how the Quebec Ride forDiabetes Research has been managedto take root in both Quebec City andLaval and reap $1.2 million in 2009.Today, slowed down by health issues,Denis Pellerin can proudly pass thetorch on to those who succeed him atthe helm of the Ride and as a boardmember with the Foundation. •

United Association of Plumbers & Pipefitters Local 213Saint John, NBDedicated to making a difference and finding a cureSeveral years ago, Barry McManusreceived a phone call inviting himto attend a JDRF corporatebreakfast in Saint John, New Brunswick.At the time, he did not know anythingabout type 1 diabetes. However,according to Barry, he left the breakfasta changed man and has been apassionate supporter of JDRF for morethan ten years.“When I heard the children with type 1diabetes speak about their experiences, itopened my eyes and changed my outlookon life. At the time, I was the businessmanager for Local 213 and I brought ayouth ambassador and parent back tospeak to our membership,” recalls Barry.“Our members were shocked at thenumber of needles these children need totake. They were really moved: a room fullof ‘tough’ pipefitters and plumbers, tearsin every eye.”Ever since Barry brought the diabetescause to Local 213, the membership hassupported him 100 per cent. Among themany causes the union supports,diabetes is the number one priority.They work all year long at variousfundraising activities, including steakdraws, bike or ATV draws andparticipate in the TELUS Walk to CureDiabetes. Over the past six years, Local213 has raised over $75,000 for JDRFand has successfully rallied other tradeunions behind the cause.“In the ten years since I’ve beeninvolved, JDRF has come a long way:every year they are gaining on a cure,”says Barry. “I keep informed, and informour union membership about advancesin therapies like the insulin pump, andother research such as detecting a genefor type 1 diabetes. These things makea big difference and I feel that verysoon, they will find a cure.”As someone whose life is nottouched directly by type 1 diabetes,Barry points to the importance ofeducation and outreach. He feels that ifmore people were aware of diabetesand how it affects children and families,then more people would surely get onboard to lend their support.“The way our union has accepted andsupported JDRF has really made meproud. I’ve been so well supported byour hard working committee and ourmembers: I go after them year after yearand they support JDRF 100 per cent,”says Barry. “The more education peopleget, the more people we can getinvolved. And when more people getinvolved, the quicker we can find acure.” •

Cinder Warren and Beth FrostStouffville, ONTenacity and hard work are in the genesCinder Warren and her motherBeth Frost come by theirtenacious attitudes and hardwork ethic honestly: back in 1830, Beth’sgreat-grandmother walked almost 100kilometres from Markham, Ontario to justoutside of Barrie, to settle land.“People say my energy must comefrom her!” says Beth, a JDRF supporterwho was involved in bringing theFoundation to Canada in 1974, alongwith fellow volunteers, Helaine and AllanShiff. “I believe success comes fromhard work, which I’ve witnessed in thesuccess of JDRF over the years.”It all began when Beth and herhusband, Mac, came home from thehospital after Cinder’s diagnosis withtype 1 diabetes over 40 years ago. Theywent to their first educational meetingwith Dr. Robert Ehrlich from the Hospitalfor Sick Children, who rallied around theidea of a fundraising organizationfocused on the search for a cure fortype 1 diabetes.“One of our first fundraising ideas forJDRF was our Rolls Royce Raffle. Ihelped to sell the $100 tickets,” explainsBeth. “This was a very unusual idea atthe time and it turned out to be popular.Everything was done manually - Iremember driving up to Newmarket todeliver a ticket.” Just a teenager at thetime, Cinder remembers tagging alongfor the drive and helping out with otherevents in the early years.Cinder’s involvement grew in the late70s and early 80s, taking a break whendiabetes management needed to takecentre stage. Now Cinder runs a golftournament in memory of her fatherevery other year, with proceeds going toJDRF. Cinder also co-chaired thePromise Ball Gala with fellow volunteerTerry Jackson in Toronto in 2007 and2009: the event raised $1.9 million and$1.7 million, respectively.“Having lived with diabetes for 40years, I’ve experienced many of the‘textbook’ complications includingretinopathy, kidney disease andcardiovascular issues,” says Cinder.“Though I’ve had to adapt toit every step of the way, Ihaven’t let it stop me fromliving.”Both mother anddaughter continue to beinvolved in volunteering andfundraising for theFoundation. In addition tofinancial gifts, Beth, whosehobby is flower arranging,has provided flowers for theGalas and other events.Cinder is turning her timeand attention to an excitingnew project in support ofJDRFI’s Artificial PancreasProject.“I would like to see two thingshappen. The first: preventing type 1diabetes from affecting kids in the firstplace. Second: treatments that minimizethe ‘collateral damage’ from gettingworse, for those of us alreadydiagnosed.” Cinder’s outlook wouldmake her tenacious great-greatgrandmotherproud: “You can bedefeated by something, or you can takeit on. So far, I’m still taking it on.” •

Successful PartnershipsThe connection between AstralMedia Inc. and JDRF dates backover 20 years, starting with AstralMedia’s founder and President, Mr. HaroldGreenberg. Mr. Greenberg passed awayfrom type 1 diabetes-relatedcomplications in 1996 but during his time,Astral Medial has been involved in a largenumber of local JDRF fundraisingactivities, including raffles, cyclethons andother events.In recent years, Astral Media has putthe power of their media outlets behindJDRF’s awareness-raising activities.Astral Media has generously providedfree air time, production of public serviceannouncements and has includedcelebrity endorsements. Hot 103 FM(Winnipeg) and Silk FM (Kelowna), bothAstral Media Radio Stations, havesupport by morning shows host Andy andTJ. Both hosts have close friends whosechild has type 1 diabetes and haveemceed the TELUS Walk to CureDiabetes for several years. In Winnipeg,Chrissy Troy, who over the past threeyears, and occasionally accompanied byco-host Ace Beaupre have emceed theTELUS Walk to Cure Diabetes in supportof Chrissy’s nephew who has 1 diabetes.In 2008, Astral Media generouslyproduced a public service announcementand provided over $95,000 worth ofairtime for Daniel Hurtubise’s Ride of aLifetime, which aired from coast to coast.Daniel, who died tragically in a roadaccident during his Ride, had embarkedupon a fundraising bike trip acrossCanada to raise $500,000 for diabetesresearch.In 2009, Astral Media Inc. donatedover $375,000 worth of airtime for anadditional public service announcementfeaturing author-composer-performerand dedicated JDRF spokesperson,Daniel Lavoie on both English and Frenchradio. •for Juvenile DiabetesVancouver businessman KyleBalagno promised his daughterTaylor he would do everything inhis power to help find a cure for hertype 1 diabetes before her 18th birthday.This commitment transformed into TeamH2V (Halifax to Vancouver) — a five manteam who cycled across Canada atrecord breaking speed in September2007. The Team made the epic ride in justeight days, set a Guinness World Record,and raised $800,000 for JDRF.Willie Cromack, a close friend of Kyle,and one of the Team H2V riders, wasinspired to carry the success of H2V tothe next level. Willie has spearheadedCyclebetes — a fundraising initiative onbehalf of JDRF that includes cross-Canada National bike relays and StudentLeadership Spin-a-Thon programs.Cyclebetes is designed to bringCanadians together. Through thisprogram, youth, cyclists, those living withtype 1 diabetes, their families and thecommunity-at-large unite to celebratewhat is possible as diabetes champions.In 2009, the inaugural year,Cyclebetes Spin-a-Thons were held innine schools, engaging thousands ofparticipants and raising hundreds ofthousands of dollars for diabetesresearch. In addition to the 7,000kilometre ride; cycling on a tandembicycle across Canada united towns andcommunities along the route and broughtthe total raised for JDRF to $450,000.The Cyclebetes team is extremelymotivated using social networking toolssuch as Facebook and Twitter, to spreadtheir message. They have connected anew group of supporters, includingteenagers, to the work of the Foundationwith the ultimate goal to create aninternational event raising awareness andfunds for diabetes research. •The relationship between TELUS andJDRF began through TELUS teammember participation, fundraisingand a company match program at variousWalks across the country. The connectionbetween TELUS and JDRF was furtherenhanced in 2005 when JDRF wasselected as charity of choice for TELUS’PERKS program, receiving a $53,000donation. In 2005, JDRF was one of thefirst grant recipients of one of the newlyestablished TELUS Community Boards,receiving $10,000 in seed money toenhance the Outreach Program inVancouver.In 2006, the Foundation’s VancouverChapter began meeting with TELUS toexplore other opportunities for theirinvolvement. In 2007, TELUS chooseJDRF as beneficiary of the TELUS SkinsGolf Tournament resulting in a donation of$200,000. The tournament broadcast onTSN was also a tremendous awarenessopportunity for JDRF.In 2008, TELUS came on board with athree-year commitment as National TitleSponsor of the TELUS Walk to CureDiabetes. However, the company’sinvolvement far exceeds just financialcontributions; through their involvement inTELUS Walk Corporate Cabinets acrossthe country, TELUS team members inspireother companies to participate, formteams, sponsor the event and volunteer.TELUS has also supported JDRF bybuying tables at local JDRF Galas incommunities across the country. Theyencourage team members to supportJDRF through their annual ‘dollars fordollars’ employee donation program:TELUS matches the employee charitablegiving donations, generating a total of$30,000 each year.In total, TELUS has provided JDRFwith over $4.3 million in support. •

Our SuccessesKeira, 6, diagnosed at 5 years of age; Leanne (Motherof Keira), 37, diagnosed at 21 years of age[ 23 ]

TELUS Walk to Cure DiabetesMaking great strides toward a cureThe TELUS Walk to Cure Diabetesis JDRF’s largest fundraisingprogram, making a significantimpact on dollars available to fundresearch each year into cures,treatments, drugs, and therapies fortype 1 diabetes.In 2009, over 45,000 Canadianscame out to walk at over 74 sites acrossCanada. Thanks to the passion andcommitment of families, corporateteams and the dedication andgenerosity of corporate sponsors, theevent raised $7.4 million. Not just afundraiser, the TELUS Walk is aninspiring opportunity for participants toget outdoors, enjoy a day of fun andfitness, and connect with other familiesliving with type 1 diabetes.Through their tireless efforts, ourincredible JDRF families, raised close to$4.5 million, representing a 4 per centincrease in participation over 2008,despite the troubled economy. Familyteam participation is increasing yearover year; currently contributing over 75per cent of TELUS Walk revenue.With 2009 marking the second yearof a three-year partnership as nationaltitle sponsor, TELUS contributed over$430,000 and attracted over 3,750TELUS team members, families andfriends. TELUS also showed theircommitment to supporting our familiesby enhancing the event day experiencewith fun tattoos, lanyards, and “I’mwalking for” credentials at a number oflocations across Canada.JDRF also values the tremendoussupport of our two national sponsorsLifeScan Canada and SunRype. Sincepartnering with JDRF, LifeScan Canada(OneTouch) has contributed over$1 million. SunRype has also generouslysupplied product and participated asWalk Teams for several years.The 2009 TELUS Walk to CureDiabetes achieved these results due tothe passion and dedication of families,corporate teams and the commitmentand tremendous generosity of corporatesponsors. •2009 Top 10 TELUS Walk to CureDiabetes Family Teams in CanadaTeam NameThe M & J TeamJoelle’s GangTeam SamanthaRockin’ Ross’Team NickBrittany’s BrigadeMighty Mia’sJordan’s Family TeamBaillie BoarsSuper Team NielsCityTorontoMontrealTorontoTorontoKelownaHamiltonEdmontonCalgaryTorontoTorontoIn 2009, the Top 10 TELUS Walk to CureDiabetes Family Teams in Canadacollectively raised over to $275,000, aninspiring and impressive achievement.[ 24 ]

Ride for Diabetes ResearchBeyond all expectationsAfast-paced and inspirationalevent, the Ride for DiabetesResearch brings corporateCanada together in friendly competitionto see who can clock the mostkilometres, show the most spirit andraise the most money.Despite approaching 2009 withcautious optimism, it was anothergrowth year for the Ride in corporateparticipation and revenue.In 2009, JDRF added a new Ridelocation in Laval, bringing our total to15 Rides across the country.JDRF also created a new NationalRide Cabinet with representation fromTD, RBC, Scotiabank, CIBC/INTRIA,National Bank, Deloitte and MTSAllstream. This powerful group of seniorexecutives is mandated to help theFoundation to grow participation withintheir respective organizations andsectors in as many Rides as possible.Deloitte led the way in nationalgrowth in 2009, increasing fundraisingby 57 per cent and participation by 58per cent.Scotiabank increased participationand revenue by an astounding 51 percent. A group of Scotia branchemployees in Central Eastern Ontariocreated the first “mini” Ride. Over 250employees in 22 branches all pedaledon one day and raised $80,000.The Insurance Sector increasedparticipation in many communities.Sun Life brought 21 teams to theWaterloo Ride and The Dominion hadteams in all sites where they haveoffices.The financial institutions continue tolead the way in number of participantsand dollars raised. The Ride builds onthis success by increasing participationfrom other sectors including Accounting,Legal and Insurance.JDRF had set a target of $5.3 million,the same amount raised in 2008. Theoverall results were astounding: theRide for Diabetes Research raised $6.2million in 2009, an increase of 15 percent in one of the most challengingeconomic years. •2009 Top 10 Corporate Ride forDiabetes Research ParticipantsCorporation NameTD Bank Financial GroupRBCScotiabank Group of CompaniesNational Bank Financial GroupCIBC / INTRIA Items IncDeloitteBell CanadaAGF Management LimitedBMO Financial GroupPricewaterhouseCoopersIn 2009, these companies were the top 10corporate participants in terms of dollarspledged. Together, they raised over $4 milliondollars toward diabetes research.Thank youA special thank you toPeter Oliver for hisyears of outstandingleadership of the Ridefor Diabetes Research.He has stepped downas national chair in 2010and has been succeeded by MattVarey from RBC. Peter has broughtthis event from one event raising$12,000 to 15 events raising $6.2million. His passion and energy havebeen an inspiration to all of us. •[ 25 ]

GalasMeeting ambitious new goalsEvery year, JDRF hosts Galaevents in cities across thecountry. Volunteers, communitypartners, donors, sponsors, staff andguests come together to raise funds,connect and celebrate in an elegantatmosphere. JDRF Gala eventsrepresent a core fundraising program forthe Foundation and in 2009 they raisedan amazing $3.1 million in eightcommunities – across the country,despite the economic downturn.Each Gala features a different theme,from Rockin’ for Research in Vancouverand the Starlight Gala in Kelowna to thePromise Ball and Gala of Hope onVancouver Island. In Ontario andQuebec, guests enjoyed the PromiseBall in Toronto and A Cure Is for Life inMontreal. Winnipeg held A Starry StarryNight, and Edmonton held a night ofDenim & Diamonds. With each uniquetheme, individual Galas offer a range ofinteresting highlights, from a diamonddraw and fun-money casino, to turn-ofthe-centuryParis ambiance, to celebrityappearances by Loverboy, MichaelBurgess, and So You Think You CanDance Canada judge Jean MarcGenereux.Gala attendees across the countryenjoy elegant dinners and receptions,silent and live auctions and featureJDRF fundraiser, Fund-A-Cure.Fund-A-Cure is JDRF’s signatureauction, providing guests with theopportunity to bid for a cure. Similar to alive auction, guests bid for the gift levelof their choice and receive a Fund-A-Cure bear and a tax receipt for theirdonation.Thank you to the many volunteersand supporters for your generosity andfor making these high-caliberfundraising events possible. •[ 26 ]

OutreachProviding families a network of supportLaunched in 2005, JDRF’s Outreach program continues togrow each year and 2009 was no exception. Theprogram provides meaningful social, emotional andpractical support and information to newly diagnosed children,adults and their families. It is also a means by which theFoundation connects with families in order to share informationabout research updates and other progress. In 2009, theOutreach program expanded once again, broadening its reachacross the country.Bag of Hope and Mentor ProgramThe Bag of Hope and Mentor programs, launched in May2008, both expanded into Quebec in 2009, therebyestablishing a coast-to-coast presence. The two programswork in tandem: the Bag of Hope, sponsored by Roche(Accu-Chek), is a kid-sized knapsack, providing information tohelp newly diagnosed families cope with the challenges ofliving with diabetes. Once a family receives a Bag of Hope,they become part of JDRF’s Family Network: the local chapterwill pair them with a mentor family to share information,experience and support.stem cell research innovations. In addition, many locationsfeatured a motivational speaker, providing inspiration andinsights into living a fulfilling life with type 1 diabetes.The following three Symposium presentations are availableas videos at www.jdrf.ca:Demystifying Stem Cell Research for Type 1 Diabetes byDavid A. Hess, Ph.D., Assistant Professor Department ofPhysiology and Pharmacology, University of WesternOntarioPreventing and Reversing Type 1 Diabetes by DesmondSchatz, M.D., Professor and Associate Chairman ofPediatrics, Medical Director, Diabetes Center Universityof Florida College of MedicineHow do we protect the pancreatic beta-cells? byDr. James D. Johnson, Ph.D., Assistant Professor,Department of Cellular and Physiological Sciences;Department of Surgery, University of British ColumbiaSpecial thanks go to national Diabetes ResearchSymposium sponsors Bayer, Lilly, Medtronic and ShoppersDrug Mart who also provided information and answeredquestions, along with booth sponsors Roche and Abbott. •Outreach Volunteer NetworkStrengthening the volunteer force behind the Outreachprogram, JDRF established a National Outreach Committee inMarch 2009. By the close of the year, the Foundation hadsuccessfully put into place an Outreach Chair andCommittee in each chapter. JDRF’s Outreach staff andvolunteers also partner together to continue to build strongrelationships with local Diabetes Education Centres acrossthe country.Diabetes Research SymposiumsIn 2008, JDRF launched its Diabetes ResearchSymposiums nationally across Canada to updatefamilies on the many advances in diabetesresearch. JDRF’s Diabetes ResearchSymposiums were further integrated into theFoundation’s programming in 2009 andexpanded to 17 communities from coast to coast.JDRF’s Diabetes Research Symposiums arenot only informative; they provide importantgathering and networking opportunities for families,researchers and other diabetes experts. Manynewly diagnosed families make meaningfulconnections with those who are more experiencedand benefit from answers and encouragement.Research topics featured at JDRF’s 2009Diabetes Research Symposiums included theartificial pancreas, gene studies, and beta cell and[ 28 ]

Government RelationsMyriam, 12, diagnosed at 2 yearsof age[ 29 ]

Government RelationsA year of making a positive impactSource: Rainer Leipscher, Canadian Press ImagesLeft to right: Harold Albrecht, M.P., Patrick Brown, M.P., Peter Braid, M.P., Andrew McKee, President and Chief Executive Officer, JDRF Canada, The Honourable Dr. GaryGoodyear, P.C., M.P., Minister of State (Science and Technology), Dan Hill, Canadian Singer and Songwriter, Stephen Woodworth, M.P. and David L. Johnston, President andVice Chancellor, University of WaterlooIn 2009, JDRF accelerated andintensified its government relationsactivities, with tremendous results. TheFoundation continued to press for positivechange for people with diabetes, identifiednew voices for advocacy efforts andstrengthened relationships with keyplayers at the federal level of government.Most notable among JDRF’saccomplishments in 2009 was thepartnership established with theGovernment of Canada to create a ClinicalTrial Network for diabetes researchthrough the Federal EconomicDevelopment Agency for SouthernOntario.Kids for a Cure Awareness WeekJDRF organized a “Kids for a CureAwareness Week” from February 16-20,2009. Participating families met withtheir Member of Parliament (MP) tomake a personal connection anddiscuss the great need for support andfunding for type 1 diabetes research.The children shared their stories ofliving with type 1 diabetes and ascrapbook they developed which wasbased on the theme “Living Proof.”This initiative was a great success,bringing the realities of diabetes homefor elected officials. Members ofParliament gained a more completeunderstanding of the disease and its[ 30 ]tremendous impact on the daily lives ofindividuals and families affected.National Grassroots SubcommitteeIn order to grow the number ofGrassroots Advocates across thecountry, JDRF launched a National Callfor Advocate Survey in June 2009. TheFoundation made a national appeal toits constituents to become moreengaged with JDRF through theGovernment Relations Program. As aresult of the survey, over 1,000individuals identified an interest inadvocating on behalf of people livingwith diabetes.Raise Your Voice“Raise Your Voice,” JDRF’s Pre-Budget Writing Campaign was launchedin September 2009. JDRF Advocatessent letters to MPs across Canada,raising awareness for diabetes and toseek funding to support our proposedpartnership with the Government ofCanada to create a Clinical Trial Networkfor diabetes research in Canada.Pre-Budget Consultations 2009On October 29, 2009, JDRFparticipated in the Standing Committee onFinance Pre-Budget Consultations inOttawa. JDRF was seeking a Pre-Budgetrecommendation from the committeesimilar to the one received in February2008 where JDRF was GeneralRecommendation number three (3) in thePre-Budget Report which stated: “Thefederal government create a specializedfund for medical research for children'shealth. In this regard, priority should begiven to the establishment of a partnershipwith Juvenile Diabetes ResearchFoundation Canada.”Launch of $33.9 Million Clinical TrialNetwork for Diabetes ResearchIn November 2009, JDRF announceda partnership with the Government ofCanada through the Federal EconomicDevelopment Agency for SouthernOntario. Through this innovative twoyearpartnership, the Government ofCanada is committing $20 million andJDRF is making a matching contributionof $13.9 million to accelerate worldclassdiabetes research in SouthernOntario by implementing a Clinical TrialNetwork for diabetes research.This partnership provides JDRF withthe opportunity to work with Canadianand international partners to buildSouthern Ontario as an internationalcentre for the development andcommercialization of cures, treatments,and medical technologies to improve thelives of people living with diabetes andits complications. •

AwarenessMika, 4, diagnosed at 12months of age[ 31 ]

Diabetes Awareness MonthEvery November, in celebration ofNational Diabetes AwarenessMonth, JDRF works to raiseawareness of the Foundation andconsciousness in support of those livingwith diabetes in Canada.In 2009, Diabetes Awareness Monthbegan with the launch of JDRF’s secondannual video contest: What a CureMeans to Me. Youth aged ten and olderwere invited to submit a video of up tothree minutes for a chance to win greatprizes, and share their personal stories,goals, and accomplishments living withtype 1 diabetes. The top three videoswere selected by a Leadership VolunteerJudging Panel, with final voting takingplace online at www.jdrf.ca by thegeneral public. Congratulations to JennaDick, who was the first place winner ofJDRF’s second annual video contest. Thetop three finalists’ videos are featured onJDRF’s website.To help raise awareness, theFoundation released its 2010 JDRFcalendar, featuring core programs,outreach, advocacy, third party events,profiles of Diabetes Champions, andways to get involved with JDRF.Calendars were distributed through JDRFChapters and 260 Walmart pharmaciesacross Canada.For World Diabetes Day (WDD),November 14, JDRF continued itspartnership with the Canadian DiabetesAssociation, and founding sponsor NovoNordisk; and welcomed new sponsor,sanofi-aventis. WDD, designated by theUnited Nations as a globally markedcelebration, is the highlight of DiabetesAwareness Month.The 2009 theme for WDD celebrated“Diabetes Champions” within the broaderdiabetes community. From people livingwith diabetes who are championsbecause of their proactive managementof the disease, to researchers who workto find a cure, to volunteers who mentor,support and drive programs, there aremany Champions to celebrate andrecognize.The www.worlddiabetes.camicrosite, launched in 2008, was updatedto reflect the Diabetes Champion themewith greater interactivity and newfeatures. The microsite featured aDiabetes Champion fundraising quiz,sponsored by sanofi-aventis where $1was donated for every completed quiz; aninteractive Diabetes Champion Gallery toshare stories; videos of DiabetesChampions featuring George Canyon,Dan Hill, Sébastien Sasseville andDeborah Sissmore, to mention a few; fullsocial media integration with Facebook,YouTube, Twitter and Flickr; and aninteractive map of Canada featuring WDDevents from human blue circles, toeducational events, to lighting of localmonuments and securing municipalproclamations.World Diabetes Day was alsocelebrated by Mrs. Laureen Harper (topmiddle photo), along with her daughterRachel and local Diabetes Champions,who constructed decorative diabetesrings (300 blue rings representing 10,000Canadians living with diabetes.) Thesedecorative diabetes rings were displayedon a tree in front of the Prime Minister’sResidence at 24 Sussex Drive, and wasilluminated in diabetes blue to celebrateWDD in the nation’s capital.Thank you to all our supportersacross the country who celebrated WDDand made it such a huge success.Other Diabetes Awareness Monthinitiatives included, a special supplementon Diabetes in the November 2009 issueof Reader’s Digest in partnership withJDRF. Entitled “The Path to the Cure,”the article featured progress generatedfrom The Research to Reality Campaign;JDRF’s cure therapeutics, a call toaction for the 2009 World Diabetes Daycampaign, and photos of JDRF YouthAmbassadors and families from theVancouver area.In partnership with Loblaws andRoche, the Foundation was featured in aDiabetes booklet — an educationalresource distributed to customers duringDiabetes Awareness Month. Fiftythousand copies were distributed in 450Loblaws pharmacies across Canada.Throughout all initiatives for DiabetesAwareness Month 2009, the theme andfocus for the month was consistent —engage and educate people on theseriousness and impact of diabetes, andto celebrate Diabetes Champions fromacross the country, and around theworld. •[ 32 ]

Continued SupportEvan; 6, diagnosed at 16months of age[ 33 ]

Corporate DonorsJDRF wishes to thank the following companies for their outstanding corporate commitment to our mission to find a curefor diabetes and its complications through the support of research and/or for contributing products and servicesthroughout the year.Abbott Laboratories, LimitedAlberto Culver Canada Inc.AMG Medical Inc. (DEX4)Astral MediaAuto Control Medical Inc.AVW-TELAVBatchfilmsBayer Inc.BD Diabetes CareBMW Group CanadaBob/FM Chum RadioCadillac Fairview CorporationCanal VieCalgary HeraldChed Concept Restaurants and Hospitality ServicesCJOH/CTVCoca Cola Ltd.Corby Distilleries Ltd.CTVglobemedia MontrealEli Lilly Canada Inc.Extreme FitnessFord Motor Company of Canada, LimitedGala EventsGenworth Financial CanadaGlobal BCHarry Winston Diamond CorporationHeritage Property CorporationHyatt Regency VancouverKinross Gold CorporationKraft Canada Inc.LifeScan Canada (OneTouch)Lick’s HomeburgersLoblaw Group of CompaniesLongo’sLucy’s Seafood KitchenMédias Transcontinental S.E.N.CMedtronic of Canada Ltd.Mitchel-Lincoln Packaging Ltd.Myron Advertising + DesignNovo Nordisk Canada Inc.Oliver & Bonacini RestaurantsOttawa Citizen Group Inc. a CanWest CompanyRBC FoundationReader’s DigestReal Canadian SuperstoreReal Estate Weekly - EdmontonRoche (Accu-Chek)Rogers Broadcasting Groupsanofi-aventis Canada Inc.Sheraton Ottawa HotelShoppers Drug MartSilpada Designs Canada CompanySobeys Inc. – EdmontonSpin Master Ltd.Sun-Rype Products Ltd.TD Bank Financial GroupTELUSThe Barrie AdvanceThe Brick GroupThe Georgia StraightVinyl 95.3Wyeth Consumer Healthcare[ 34 ]

Major DonorsJDRF’s From Research to Reality Honour Roll$2,000,000−− Christine and Herschel Victor$1,000,000−−Marsha and Aubrey Baillie−−Bonnie and Terry Jackson−−Boston Pizza Foundation−−TELUS and its TeamMembers$500,000 - $999,999−−RBC Foundation−−Auction for a Cure$250,000 – $499,999−−BD Diabetes Care−−Cyclebetes 2009−−Galen Anderson-Dickie andthe late Paul Dickie$100,000 – $249,999−−A.W.B. CharitableFoundation−−Herbert Black−−BMO Financial Group−−Succession Fedora GirouxBeaudoin−−Neil and Katherine Camarta−−Estate of Robert Chisholm−−CIBC−−The Cleghorn Family−−Estate of Ron Courneyea−−Alex and Audrey Davidson−−Diabetes Canada Trust−−Paul and Diane Erickson−−Estate of Robert JohnFischer−−Larry and Carol Hagan−−Robert Hindle and Family−−Gabor and Eva Jellinek andDana Jellinek−−The Josephson Family−−Jason Kelly Classic GolfTournament−−Irwin and Sheila Lancit−−Estate of Leah Kessler−−LifeScan Canada(OneTouch)−−Robert and Marie MacRae−−Robert McLeish−−National Bank of Canada−−Novo Nordisk Canada Inc.−−Roche (Accu-Chek)−−Scotiabank Group ofCompanies−−The Shiff Family−−Rhoda and RobertVineberg−−4 Anonymous$50,000 – $99,999−− Armour TransportationSystems/The Armour Family−−Geoff and Sandie Beattie−−Simon and Brenda Benattar−−BMO Mastercard−−Bridge of Hope CharitableFoundation−−Broer/Marshall Family−−Tye and Janet Burt−−Douglas and Joanne Cohen−−CPI Canada−−Deloitte & ToucheFoundation Canada−−The Economical InsuranceGroup−−Peter and Kim Enns−−Patricia and Ronald Forbes−−Wayne and Isabel Fox−−Mike and Mary Lee Hopkins−−Susan Kornhauser inmemory of Emanuel (Bob)Kornhauser−−The Leibel Family−−Estate of Lucy Lynn−−The McKee Family−−Norm Meldrum CharitableFoundation−−Maureen and Peter Oliver−−Ride of a Lifetime−−sanofi-aventis Canada Inc.−−Ryan and Karen Shay−−Estate of Margaret CunardSmith−−TAQA North−−TD Bank Financial Group−−Zeller Family Foundation−− 5 Anonymous$25,000 – $49,999−−Abercrombie Foundation−−Aconcagua Team−−Alberta Building TradesCouncil CharitableFoundation−−Alberta Culture andCommunity Spirit−−The Aquilini Family−−Bell Canada−−Estate of John SpencerBigham−−BMO Financial Group –Windsor District CharitableGolf Tournament−−Scott Bolton−−J. Armand BombardierFoundation−−Thomas Alan BuddFoundation−−Canada Safeway Limited−−Carleigh LeClair GolfClassic−− Colliers Macaulay Nicolls Inc.−−Cottonwood Shots for Kids−−Mary and GordonChristopher Foundation−−Michael Cruickshank−−Penny and GordonEchenberg FamilyFoundation−−Kenneth and JanisFinkelstein−−Steve and Heather Frishling−−Jimmy and Gail Garfinkle−− Don Garner and Kim Borhen−−GMP Securities Ltd.−−Grant Family GolfTournament−−Valerie and Brian Harris−−Estate of Marianne Hart−−Bryan and Claire Haynes−−Jewish CommunityFoundation of Montreal−−Stephen Kaplan FamilyFoundation−−Kelowna Golf and CountryClub Ladies Charity GolfTournament−−Evelyn and David Kozloff−−Karen and Lorn Kutner−−Barb and Todd Millar−−Annette Oelbaum & Family– In Memory of RonaldOelbaum−−Tim and Lois O’Neill−− Phillips, Hager & NorthInvestment Management Ltd.−−The Printing House Limited−−Brian Randall Golf forDiabetes Tournament−−Regina JDRF GolfTournament−−George and TannisRichardson/JamesRichardson & Sons Ltd./Richardson Foundation−−The Royal Conservatory ofMusic−−Rotating Right Inc.−−Yolanda Stepien and DanMcLeod−−Source Cable−−Estate of Maureen Swaffer−−United Way of Ottawa−−Estate of Henry WilliamThomas Tansley−−TeamONE – Machu Picchu−−The Thomson Corporation−−Time Development Ltd.−− Yolande Tsampalieros andthe late Gabriel Tsampalieros−−UBS Securities Canada−−Billy and Kelly Vance−−Estate of Betty Ann MarionVodden−−ZLC Foundation CharityGolf Tournament−− Dr. Sidney and Debra Zucker−−3 Anonymous$10,000 – $24,999−−Felicia and Arnold AaronFoundation−−Alberta Regional Council ofCarpenters−−All Hockey InternationalBall Hockey Tournament−−Stephen Ames Foundation−−Dan Angel Tee It UpTournament−−Robert C. and Barbara J.Armstrong−−Atlantic Province TruckingAssociation−−Mary Ann Azzarello−−Steve Babor−−Bank of America MerrillLynch−−Barbecues Galore−−Estate of Pauline Bergeron-Houle−−Better Beef Limited−− Beverly Golf & Country Club−−David Bird−−BMO Employee CharitableFoundation−−Boutique Jacob Inc.−−Boys’ Co−−Brass Hill InvestmentsLimited−−Estate of Beverley PearlBridge−−J. Edward Brockhouse−−Builders Energy ServicesLtd.−−Canadian JewellersAssociation−−Robert & Carmen Carbone−−Tim Casgrain−−CI Investments−−CIBC Wood Gundy−−IA Clarington−−Colliers International−−Community Partners ofPeel Regional Police−−Gordon and PatriciaCunningham−−Dancing for the Children−−DELL Canada[ 35 ]

Major Donors−−Davies Ward Phillips &Vineberg−−Mary Jane Devine and MikeCyr−−Estate of Elizabeth JeanDickson−−Dinner with the Chief –Peel Regional Police−−Heather and Randy Doetzel−−Dominion Nickel Alloys Ltd.−−Ekota Central Ltd.−−Electri-Tech Services Inc.−−Eli Lilly Canada Inc.−−Mike Fair Golf Tournament−−Ron Ferguson−−Sheldon and NormaFinkelstein−−Margot and BrianFitzpatrick−−Eldon and Anne FooteFoundation at EdmontonCommunity Foundation−−Freedom 55 Financial−−The Frocktail Party−−Futurion−−Gamma - DynacareMedical Laboratories−−Estate of James Geddes−−The Globe and Mail−−Goodmans LLP−−Robert and MaryGoodfellow−−Phyllis and Lou Gordon−−Leila Bell-Irving Grauer andChristopher Grauer−−In Honour of Eric Gray−−Great-West Life AssuranceCompany−−Tom and Dee Dee Green−−Fran and Doug Grundman−−Hamilton Bulldogs HockeyClub−−Haywood Securities Inc.−−Trevor Haynes−−Estate of B.T. Hazelton−−HB Group InsuranceManagement Ltd.−−Heffel Gallery Ltd.−−William and Joy Hibbard−−Hindle and Associates−−Frank and Anita Holler−−Prentice Lee and AngelaHomer−−Estate of Ernestine Hopkins[ 36 ]−−Richard Anstett−−Marsha and Aubrey Baillie−−M. Bjegovich−−Carol and Larry Hagan−−Bonnie and Terry Jackson−−Harvey Kestenberg−−The Horlick Family−−HSBC−− IBM Canada Ltd.Employees’ Charitable Fund−−Milan and Maureen IlichFoundation−−IMS Health Canada−−Independent Order ofForesters−− Independent Planning Group−−Cindy Innes and the lateDrew Innes−−International Marriott−−Iovate Health Sciences Inc.−−Ivanhoe-CambridgeLeaseholds−−Jacob−−Jammin’ for JD−−JC Clark Ltd.−−Peter Jensen and SandraStark−−JJ Charity Golf Tournament−− Joe Johnson Equipment Inc.−−Johnson & Johnson Groupof Companies−−Yvonne Kala−−Jeffrey Kerbel−−Shawn Kimel−−Kiwanis Club−−Debbie and DannyKornhauser−−Kraft Canada Inc.−−KPMG−−Estate of Jean TempletonLindsay−−Allen and Lisa Lougheed−−The Lougheed Block Inc.−−Jerry and Joan Lozinski−−Peter Lyall and TeddiOrenstein Lyall−−Tamara and JustinMacCormack−−Manitoba Building TradesGolf Tournament−−Manitoba Mustangs’Charity Hockey Fund –Garth Lancaster−−Maples Dental Centre−−Allan Markin−−Masonic Foundation ofOntario−−Estate of Donald EdwardMcCarthy−−Medavie Blue Cross−−Menkes Developments Ltd.−−Steven and Ofra Menkes−−Mike Fair ChevroletCadillac Ltd.−−Elaine and Barry Mintz−−City of MississaugaCanada Day Event−−Mitchel-Lincoln PackagingLtd.−−Monarch Corporation−− Morgan Stanley Canada Ltd.−−Motorola Canada Ltd.−−Ian and Louise Mummery−−New Brunswick BuildingTrades Council/CarpentersTraining Centre−−NCR Canada Ltd.−−Nico’s Gala to Find a Cure−−The Night to End Diabetes−−Alan and Shelly Norris−−North AmericanConstruction Company−−Jessica Oliver−−Oringer Family Foundation−− Osler Hoskin & Harcourt LLP−−Ottawa Citizen Group Inc. aCanWest company−−PaperLinx Canada−−Travis Peckham−−Gregory Perkell−−Pfizer Canada Inc.−− David and Patrice Poppleton−−Protech Chemicals Ltd.−−Jim Rager−−Real Canadian Superstore−−Rebekah Assembly ofOntario−−Redbourne Group HoldingsInc.−−The Cyril and Dorothy, Joeland Jill Reitman FamilyFoundation−−Reitmans (Canada) Inc.−−Peter and Greta Reiskind−−The Richter CharitableFoundation−−Michael RosenbloomFamily Foundation−−Rosenbloom Groupe Inc.−−Larry and Suzanne Ross−−RPM TechnologiesCorporation−−In Memory of Raymond H.RudinThe Beta Society Legacy Gift Honour Roll−−Beverley Kinshella−−Donald and Dorothy Lawless−−Robert McLeish−−Paula Mussman−−Lorraine Pollock−−George and Tannis Richardson−−The Sabiston Family−−Estate of Theresa HelenSansom−−Saskatchewan ProvincialBuilding & Trades CouncilGolf Tournament−−Save-On-Foods−−Doug & Jan Schafer−−Robert Scott−−Joe Schlesinger−−Robert and Jessica Shelley−−The Sharf Family – Inmemory of Rosslyn Sharf−−Lorne Shiff−−Standard Life−−Dr. Melvin and RuthSteinhart−−Stokes−−Stonehouse Group Inc.−−Sunlife Financial Services−−Sun-Rype Products Ltd.−−TD Securities−−Teachers Have Hart−−Torys LLP−−Tournament of Triumph –Hamilton Police Services−−Morris and Paula Trefler−−United Way of Calgary andArea−−United Association ofPlumbers and Pipefitters– Local 213−−Vac Aero International Inc.−−Gail Victor−−Cinder Warren−−Waterloo, Wellington,Dufferin & Grey Building &Construction TradesCouncil Golf Tournament−−Webkinz Foundation−−Westfair Foods Inc.−−Andrew D. Wilkin−−Bruce and Beatrijs Williams−−Helen and Jackson Wittup−−E. Maurice Wolfe−− WRD Borger Construction Ltd.−−14 Anonymous−−Margaret Taylor−−Paul and Louise Shewfelt−−Helaine and Allan Shiff−−David Skelly−−Dr. and Mrs. D. Wright−−7 Anonymous

Canadian Research Funded in 2009Juvenile Diabetes Research Foundation wishes to recognize and express its deepest gratitude to donors who generouslycommitted funds to support these research grants.AutoimmunityAnderson, Colin, Ph.D.Research Grant AwardModulation of Co-Inhibitory Pathways in Tolerance andAutoimmunityThe Governors of the University of Alberta, Edmonton, ABDelovitch, Terry, Ph.D.Innate Immunity GrantNovel Strategies for Innate Immune Modulation of Type 1DiabetesRobarts Research Institute, London, ONDutz, Jan, M.D., F.R.C.P.C.Mucosal ImmunityIntestinal Barrier Function and TLR Signaling in Type 1DiabetesUniversity of British Columbia, Vancouver, BCLabrecque, Nathalie, Ph.D.Immune MemoryDelineating the Role of Memory T Cells in AutoimmuneDiabetesHôpital Maisonneuve-Rosemont, Centre de Recherche,Montreal, QCLesage, Sylvie, Ph.D.Immune MemoryElimination of Pathogenic T Cells through a RareRegular T Cell SubsetHôpital Maisonneuve-Rosemont, Centre de Recherche,Montreal, QCMacPherson, Andrew, M.D., F.R.C.P.C.Mucosal ImmunityType 1 Diabetes Protection through CommensalIntestinal Bacterial ExposureMcMaster University, Hamilton, ONPiccirillo, Ciriaco, Ph.D.Research Grant AwardIntegrating Genetics with Markers of Immune ResponseMcGill University Health Centre, Montreal Children’sHospital, Montreal, QCPolychronakos, Constantin, M.D.Research Grant AwardMechanisms Involved in Novel Genetic Associations withType 1 DiabetesMcGill University Health Centre, Montreal Children’sHospital, Montreal, QCPolychronakos, Constantin, M.D.Research Grant AwardFunctional evaluation of IDDM lociMcGill University Health Centre, Montreal Children’sHospital, Montreal, QCSantamaria, Pere, M.D., Ph.D.Research Grant AwardA Novel Vaccine for the Prevention and Cure of Type 1DiabetesUniversity of Calgary, Calgary, ABSantamaria, Pere, M.D., Ph.D.Research Grant AwardPeptide-MHC-coated Paramagnetic Nanoparticles asAnti-Diabetogenic VaccinesUniversity of Calgary, Calgary, ABSantamaria, Pere, M.D., Ph.D.Academic R&DPeptide MHC Class-I Coated Gold Nanoparticles fortreatment of Type 1 Diabetes.University Technologies International, Inc., Calgary, ABTan, Rusung, M.D., Ph.D.Research Grant AwardMechanisms of Autoimmune Regulation by Natural KillerCellsUniversity of British Columbia, Vancouver, BCWarnock, Garth, M.D., M.Sc., F.R.C.P.C.Innovative GrantCharacterization of T-cell Costimulatory Molecules inPancreata from IAPCDUniversity of British Columbia, Vancouver, BCRegenerationTransition Therapeutics, Dr. Tony CruzIndustry GrantStimulation of Islet Cell Regeneration in Type 1 Diabeteswith Byetta and GastrinTransition Therapeutics, Toronto, ONDrucker, Daniel, M.D.Research Grant AwardEnhancing Incretin Action for the Treatment of DiabetesUniversity Health Network, Toronto, ONHickson, Marc, M.D.Innovative GrantBeta Cell Imaging with F-18-labelled Glibenclamide-Glucose Conjugate by PETMcGill University, Montreal, QCJohnson, James, Ph.D.Career Development AwardRegulation of the Beta-Cell Life Cycle by InsulinUniversity of British Columbia, Vancouver, BC[ 37 ]

Canadian Research Funded in 2009Johnson, James, Ph.D.Research Grant AwardRaf-1 in Beta Cell Survivial, Proliferation and InsulinSignalingUniversity of British Columbia, Vancouver, BCJohnson, James, Ph.D.Partnership – Beta Cell SurvivalComprehensive High-Content Screening to PreventBeta-Cell ApoptosisUniversity of British Columbia, Vancouver, BCKorbutt, Greg, Ph.D.BioengineeringBioengineering a Highly Visualized Ectopic Site for IsletTransplantationThe Governors of the University of Alberta, Edmonton, ABKieffer, Timothy, Ph.D.Research Grant AwardTargeted Expression of Insulin to Intestinal Endocrine CellsUniversity of British Columbia, Vancouver, BCMacDonald, Patrick, Ph.D.Career Development AwardMetabolic and Immunologic Interactions in Islet GraftFunction and LossThe Governors of the University of Alberta, Edmonton, ABPolychronakos, Constantin, M.D.Special GrantA Novel Gene Necessary for the Development of theEndocrine PancreasMcGill University Health Centre, Montreal Children’sHospital, Montreal, QCRabinovitch, Alex, M.D.Academic R&DCombination Therapy with a Dipeptidyl Peptidase-4Inhibitor and a Proton Pump Inhibitor: A Novel Therapyfor Type 1 DiabetesUniversity of Alberta, Edmonton, ABShapiro, James, M.D.Centre GrantIslet Protection, Regeneration and New Sites forImplantationThe Governors of the University of Alberta, Edmonton, ABStrom, Alexander, Ph.D.Postdoctoral Fellowship AwardPhysiological Role of PrP(c) in Pancreatic Beta-CellsOttawa Health Research Institute, Ottawa, ONWang, Qinghua, M.D., Ph.D.Research Grant AwardBeta-cell Regeneration & Immunoregulation forTreatment of Type 1 DiabetesSt. Michael’s Hospital, Toronto, ONReplacementGaisano, Herbert, M.D.Research Grant AwardControlling Alpha-Cell Glucagon Secretion to OptimzeGlycemic ControlUniversity of Toronto, Toronto, ONKieffer, Timothy, Ph.D.ProgenitorTransgenic Pigs with Insulin Producing Gut K-CellsUniversity of British Columbia, Vancouver, BCLynn, Francis, Ph.D.Advanced Postdoctoral FellowshipThe Role of microRNA in Development of the PancreaticBeta CellUniversity of British Columbia, Vancouver, BCMacDonald, Patrick, Ph.D.Innovative GrantNon-adenoviral Peptide Modulator Expression toImprove Islet Graft FunctionThe Governors of the University of Alberta, Edmonton, ABNostro, Maria Christina, Ph.D.Post-doctoral Fellowship AwardDerivation of Functional Beta Cells from HumanEmbryonic Stem CellsUniversity Health Network, Toronto, ONvan der Kooy, Derek, Ph.D.Scholar AwardPancreatic Stem CellsUniversity of Toronto, Toronto, ONWarnock, Garth, M.D., M.Sc., F.R.C.P.C.Research Grant AwardImproving Islet Graft Survival by Blocking NegativeCostimulatory PathwaysSt. Michael’s Hospital, Toronto, ONWright, James R. M.D., Ph.D.Research Grant AwardTilapia Islet Cell Biology-Characterization forXenotransplantationThe University of Calgary, Calgary, ABZandstra, Peter, Ph.D.BioengineeringEngineering Pancreatic Specifications from HumanPluripotent Stem CellTerrence Donnelly Centre for Cellular and BiomolecularResearchUniversity of Toronto, Toronto, ONComplicationsBoright, Andrew, Ph.D., M.D.Research Grant AwardGenetic Studies of the SOD1 locus and DiabeticNephropathyUniversity of Toronto, University Health Network,Toronto, ON[ 38 ]

Canadian Research Funded in 2009Fernyhough, Paul, Ph.D.Research Grant AwardDevelopment of Therapeutic Candidates to TreatDiabetic NeuropathySt. Boniface General Hospital, Winnipeg, MBFernyhough, Paul, Ph.D.Research Grant AwardMechanism of Distal Axonal Degeneration in DiabeticSensory NeuropathySt. Boniface General Hospital, Winnipeg, MBFernyhough, Paul, Ph.D.Academic R&DHigh Content Screening of Sensory NeuronsSt. Boniface General Hospital, Winnipeg, MBPacaud, Danièle, M.D.Academic R&DCorneal Confocal Miscroscopy to Detect DiabeticNeuropathy in ChildrenUniversity of Calgary, Calgary, ABPerkins, Bruce, M.D.Academic R&DCorneal Nerve Fiber Density as a Biomarker of EarlyNeuropathyUniversity Health Network, Toronto, ONToth, Cory, M.D., F.R.C.P.C.Innovative GrantNFkB and RAGE-Mediated Changes in the Diabetic BrainUniversity of Calgary, Calgary, ABJDRF Clinical Centre for IsletTransplantation, University of AlbertaJames Shapiro, M.D., Ph.D., Centre Director,University of Alberta, Edmonton, ABJeffery Johnson, Ph.D., Co-DirectorJohn Elliott, M.D., Ph.D., Co-DirectorGreg Korbutt, Ph.D., Co-DirectorEdmond Ryan, M.D., Co-DirectorRay Rajotte, Ph.D., Co-DirectorDavid Bigman, M.D., Co-InvestigatorNorman Kneteman, M.D., Co-InvestigatorTo advance outcomes and minimize risk of clinical islettransplantation, to study impact of successful islettransplant in control of secondary diabetes-relatedcomplications, quality of life and cost-utility benefit, andto optimize recovery of islets to enhance success withsingle donor islet transplants.Centre Sponsor: Boston Pizza International Inc.Centre Sponsor: Alice and Russell M. ArtztCentre Friend: The David & Molly Bloom JuvenileDiabetes FundCentre Friend: Galen Anderson Dickie and the latePaul A. DickieCentre Friend: Novo Nordisk Canada Inc.Centre Friend: RBC FoundationCentre Patron: The Mr. & Mrs. Edsel B. Ford IIFord Motor Company JuvenileDiabetes FUNDZochodne, Douglas, M.D.Interconnecting and Synergistic PathwaysDiabetic Neuropathy, Neuoronal Insulin and itsInteraction with Age-RageUniversity of Calgary, Calgary, ABPARTNERSHIPCanadian Institutes of Health Research – Canada VPartnership ProgramOttawa, ON Kieffer, Timothy, Ph.D.Beta Cell Regeneration for Diabetes Rosenberg, Lawrence, Ph.D.Design and Development of an InnovativeBioengineered Process for the Production ofPancreatic Endocrine Tissue for Treatment ofDiabetes Mellitus[ 39 ]

Financial Review 2009Consolidated Balance SheetAs at December 31, 20092009 $ 2008 $Consolidated Statement of Public Support, Other Revenues and Expensesfor the year ended December 31, 20092009 $ 2008 $AssetsCurrent AssetsCash 1,705,429 6,388,582Short-term investments 7,786,082 876,122Accounts receivable 512,659 635,011Prepaid expenses and other assets 186,581 201,95510,190,751 8,101,670Capital assets 521,894 380,30810,712,645 8,481,978LiabilitiesCurrent LiabilitiesAccounts payable, accrued liabilitiesand deferred support 738,502 708,154Deferred leasehold inducement 235,614974,116 708,154Net AssetsUnrestricted 9,653,029 7,688,324Restricted for endowment purposes 85,500 85,50010,712,645 8,481,978Public Support RevenuesCampaigns 21,936,455 20,537,090Direct response 159,043 352,10222,095,498 20,889,192Other revenuesInvestment Income 30,019 211,353Unrealized gain on short-term investments 6,227 12,87036,246 224,22322,131,744 21,113,415Less: Direct expenses (4,593,992) (4,541,193)17,537,752 16,572,222Other expensesProgram servicesResearch support 8,877,987 9,782,075Public education and advocacy 3,499,577 3,738,78412,377,564 13,520,859Supporting servicesManagement and general 1,144,088 1,139,261Fundraising 2,051,395 2,143,1733,195,483 3,282,43415,573,047 16,803,293Surplus (deficit) for the year 1,964,705 (231,071)Functional Expenses (000’s)Management and General 7%Fundraising 13%Public Support and Other Revenues (000’s)• Direct Response$159• Campaigns/Special Events$21,936Direct Response 1%• Management and General$1,144• Fundraising$2,051• Research Support &Education Related to ResearchResearch Support & Education$12,378Related to Research 80% Campaigns/Special Events 99%Report of ManagementManagement is responsible for the preparation of the Foundation’s financial statements and other financial information in this report. This responsibilityincludes maintaining the integrity and objectivity of the financial records. The Foundation maintains a system of internal controls designed to provideassurance that its records include the transactions of its operations.The financial statements have been reported on by the Foundation’s auditors, PricewaterhouseCoopers LLP, Chartered Accountants. The Board ofDirectors, through its Finance Committee, is responsible for determining that management fulfills its responsibilities in the preparation of the financialstatements, and ensures the financial and operational controls of the Foundation are adequate.The Audit Committee reviews the financial statements and meets with the auditors. The auditors have full and free access to management, the FinanceCommittee, and the Audit Committee in carrying out their work.The data on this page has been extracted and summarized from the audited financial statements. A complete set of financial statements is available uponrequest from the Finance department at (647) 789-2002. Charitable business number 11897 6604 RR0001[ 40 ]

Directors & ChaptersBoard of Directors and OfficersAubrey Baillie, Chair of the Board(Toronto, ON)Alex Davidson, Treasurer(Toronto, ON)Robert Hindle, Past Chair(Montreal, QC)Dr. David Kozloff, Secretary(Montreal, QC)Andrew McKee, President & CEO(Toronto, ON)Brad Buchanan (Kelowna, BC)Mike Cyr (Vancouver, BC)Stuart Dalgleish (Calgary, AB)Darrin Davis (Winnipeg, MB)Sheldon Finkelstein, MD (Toronto, ON)Bryan Haynes (Calgary, AB)Mike Hopkins (Santa Barbara, CA)Jennifer Kotzeff (Ottawa, ON)Jonathan Lister (Toronto, ON)Mollie Miller (Las Vegas, NV)Sean Murray (Pictou, NS)Peter Oliver (Toronto, ON)Denis Pellerin (Montreal, QC)Lorne Shiff (Toronto, ON)Matt Varey (Toronto, ON)Bruce Williams (Toronto, ON)National Support OfficeJuvenile Diabetes ResearchFoundation Canada2550 Victoria Park Avenue, Suite 800Toronto, ON M2J 5A9Tel: (647) 789-2000Toll Free: 1.877.CURE.533Atlantic RegionHalifax1658 Bedford Hwy. Suite 2055Bedford Place MallBedford, NS B4A 2X9Tel: (902) 453-1009Toll Free: 1.888.439.5373MonctonTel: (506) 852-4415Saint John, NB37 Neck RoadSummerville, NB E5S 1A2Tel: (506) 763-0001St. John’s, NLP.O. Box 76, 8 Track RoadMobile, NL A0A 3A0Tel: (709) 334-3312B.C. & Yukon RegionVancouver6450 Roberts Street, Suite 150Burnaby, BC V5G 4E1Tel: (604) 320-1937Toll Free: 1.877.320.1933Victoria389 Crystalview TerraceVictoria, BC V9B 5S5Tel: (250) 220-5857Kamloops347 West Seymour StreetKamloops, BC V2C 1E8Tel: (250) 374-0599KelownaBox 22037, Capri Centre POKelowna, BC V1Y 9N9Tel: (250) 868-1014North Central Alberta & NWT RegionEdmonton17321 – 108 Avenue NWEdmonton, AB T5S 1G2Tel: (780) 428-0343North Eastern Ontario RegionOttawa75 Albert Street, Suite 902Ottawa, ON K1P 5E7Tel: (613) 244-4818Toll Free: 1.866.796.5373Prairie RegionWinnipeg191 Lombard Avenue, Suite 1101Winnipeg, MB R3B 0X1Tel: (204) 953-4477Regina/SaskatoonP.O. Box 3924Regina, SK S4P 3R8Tel: (306) 543-5451Quebec RegionMontreal615 Rene-Levesque Blvd. West,Suite 330Montreal, QC H3B 1P5Tel: (514) 744-5537Toll Free: 1.877.634.2238Southern Alberta RegionCalgary1608-17th Avenue S.W., Suite 204Calgary, AB T2T 0E3Tel: (403) 255-7100South Central Ontario RegionMississauga7195 Millcreek DriveMississauga, ON L5N 4H1Tel: (905) 608-8067Barrie1013 Bayfield Street NorthMidhurst, ON L0L 1X1Tel: (705) 792-4833Toll Free: 1.866.413.5373Hamilton202 – 180 James Street SouthHamilton, ON L8P 4V1Tel: (905) 524-5638Toll Free: 1.866.602.6662South Western Ontario RegionWaterloo684 Belmont Avenue W., Unit 103Kitchener, ON N2M 1N6Tel: (519) 745-2426London309 Commissioners Road, Unit A #2London, ON N6J 1Y4Tel: (519) 641-7006Windsor3347 Randolph AvenueWindsor, ON N9E 3E8Tel: (519) 972-6676Toronto RegionToronto2550 Victoria Park Avenue, Suite 800Toronto, ON M2J 5A9Tel: (647) 789-2000Toll Free: 1.877.CURE.533[ 41 ]

Mika, 4, diagnosedat 12 months.Juvenile Diabetes Research Foundation2550 Victoria Park Avenue, Suite 800Toronto, ON M2J 5A91.877.CURE.533 | 647.789.2000www.jdrf.ca